Skip to main content
Intended for healthcare professionals
Free access
Other
First published online January 1, 2016

Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society

Tracy Glauser, MD [email protected], Shlomo Shinnar, MD, PhD, David Gloss, MD, Brian Alldredge, PharmD, Ravindra Arya, MD, DM, Jacquelyn Bainbridge, PharmD, Mary Bare, MSPH, RN, Thomas Bleck, MD, W. Edwin Dodson, MD, Lisa Garrity, PharmD, Andy Jagoda, MD, Daniel Lowenstein, MD, John Pellock, MD, James Riviello, MD, Edward Sloan, MD, MPH, and David M. Treiman, MDView all authors and affiliations
Volume 16, Issue 1
https://doi.org/10.5698/1535-7597-16.1.48

Abstract

CONTEXT: The optimal pharmacologic treatment for early convulsive status epilepticus is unclear. OBJECTIVE: To analyze efficacy, tolerability and safety data for anticonvulsant treatment of children and adults with convulsive status epilepticus and use this analysis to develop an evidence-based treatment algorithm. DATA SOURCES: Structured literature review using MEDLINE, Embase, Current Contents, and Cochrane library supplemented with article reference lists. STUDY SELECTION: Randomized controlled trials of anticonvulsant treatment for seizures lasting longer than 5 minutes. DATA EXTRACTION: Individual studies were rated using predefined criteria and these results were used to form recommendations, conclusions, and an evidence-based treatment algorithm. RESULTS: A total of 38 randomized controlled trials were identified, rated and contributed to the assessment. Only four trials were considered to have class I evidence of efficacy. Two studies were rated as class II and the remaining 32 were judged to have class III evidence. In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intramuscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular midazolam, intranasal midazolam, and buccal midazolam are probably effective (Level B). No significant difference in effectiveness has been demonstrated between intravenous lorazepam and intravenous diazepam in adults or children with convulsive status epilepticus (Level A). Respiratory and cardiac symptoms are the most commonly encountered treatment-emergent adverse events associated with intravenous anticonvulsant drug administration in adults with convulsive status epilepticus (Level A). The rate of respiratory depression in patients with convulsive status epilepticus treated with benzodiazepines is lower than in patients with convulsive status epilepticus treated with placebo indicating that respiratory problems are an important consequence of untreated convulsive status epilepticus (Level A). When both are available, fosphenytoin is preferred over phenytoin based on tolerability but phenytoin is an acceptable alternative (Level A). In adults, compared to the first therapy, the second therapy is less effective while the third therapy is substantially less effective (Level A). In children, the second therapy appears less effective and there are no data about third therapy efficacy (Level C). The evidence was synthesized into a treatment algorithm. CONCLUSIONS: Despite the paucity of well-designed randomized controlled trials, practical conclusions and an integrated treatment algorithm for the treatment of convulsive status epilepticus across the age spectrum (infants through adults) can be constructed. Multicenter, multinational efforts are needed to design, conduct and analyze additional randomized controlled trials that can answer the many outstanding clinically relevant questions identified in this guideline.

Background

Traditionally, brief seizures are defined as lasting less than 5 minutes, while prolonged seizures last between 5 and 30 minutes; status epilepticus is defined as more than 30 minutes of either 1) continuous seizure activity or 2) two or more sequential seizures without full recovery of consciousness between seizures (1). The 30-minute definition is based on the duration of convulsive status epilepticus that may lead to permanent neuronal injury by itself (2). Since the majority of seizures are brief, and once a seizure lasts more than 5 minutes it is likely to be prolonged (3), status treatment protocols have used a 5-minute definition to minimize both the risk of seizures reaching 30 minutes and the adverse outcomes associated with needlessly intervening on brief, self-limited seizures (2, 4). This guideline follows this convention and, for purposes of treatment, uses the term status epilepticus to represent studies involving both prolonged seizures and traditionally defined status epilepticus.
Status epilepticus presents in several forms: 1) convulsive status epilepticus consisting of repeated generalized tonic–clonic (GTC) seizures with persistent postictal depression of neurologic function between seizures; 2) nonconvulsive status epilepticus where seizures produce a continuous or fluctuating “epileptic twilight” state; and 3) repeated partial seizures manifested as focal motor signs, focal sensory symptoms, or focal impairment of function (e.g., aphasia) not associated with altered awareness (epilepsia partialis continua).
Between 50,000 and 150,000 Americans each year have status epilepticus (5–7), with mortality estimated at less than 3% in children but up to 30% in adults (5, 6, 8). The goal of therapy is the rapid termination of both clinical and electrical seizure activity, since appropriate and timely therapy of status epilepticus reduces the associated mortality and morbidity (9). Ultimately, the prognosis is most strongly related to the etiology, duration of status epilepticus, and the age of the patient (10–12). Basic critical care and emergency principles of therapy such as supporting respiration, maintaining blood pressure, gaining intravenous (IV) access, and identifying and treating the underlying cause have achieved widespread acceptance and are routinely implemented by both neurologists and non-neurologists. Despite this recognition of the need to address status epilepticus as a critical care emergency, the goals of therapy and approaches to the pharmacologic treatment of status epilepticus continue to vary dramatically. Unfortunately, patients still receive inadequate treatment for a variety of reasons including, but not limited to, therapy aimed at reduction instead of termination of seizures, use of inefficient therapies such as sedatives and paralytics, and administration of insufficient anticonvulsant doses.
In 1993, the Epilepsy Foundation of America asked its professional advisory board to convene a working group of experts to develop a treatment protocol and related educational materials depicting the best current medical management of convulsive status epilepticus. The subsequent consensus guideline provided physicians with a consistent, rational approach (2). Over the past 2 decades, new medical therapies and new clinical trial data have emerged relating directly to the treatment of this most feared type of seizure activity. Coupled with the acceptance of evidence-based rather than consensus-based guidelines, the Epilepsy Foundation in 2004 and the American Epilepsy Society in 2012 began the process of reevaluating the existing medical literature and developing a new guideline. This writing team started their activity on behalf of the Epilepsy Foundation and completed their task with the support of the American Epilepsy Society.

Purpose of this Guideline and Definition of Terms

The goal of this current guideline is to provide evidence-based answers to efficacy, safety, and tolerability questions regarding the treatment of convulsive status epilepticus and to synthesize these answers into a treatment algorithm. This guideline focuses on convulsive status epilepticus because it is both the most common type of status epilepticus and is associated with substantial morbidity and mortality. Anticonvulsant “efficacy” is the ability of the drug to stop convulsive status epilepticus, “tolerability” involves the “incidence, severity and impact” of anticonvulsant related adverse effects (13, 14), “effectiveness” encompasses both anticonvulsant efficacy and tolerability, and “safety” refers to life-threatening adverse events.
The guideline's recommendations aim to help clinicians worldwide understand the relevant existing evidence for treatment of patients with status epilepticus. The guideline is intended for use by individual clinicians, hospitals, health authorities, and providers. We recognize that this guideline will need local scrutiny and adjustment in order to make it relevant to the social and economic environments in which it will be used. This process should lead to a sense of ownership of any adjusted guideline, which will be essential for effective implementation and will lead to improvement in healthcare outcomes for people with convulsive status epilepticus.

Scope of this Guideline

This guideline will address the evidence regarding the treatment of convulsive status epilepticus. For the purposes of this guideline, only studies that enrolled subjects having a seizure duration of at least 5 minutes were considered. The guideline's analysis is presented by subject age (adult studies, pediatric studies), since studies arbitrarily focused on either adult or pediatric subjects. The guideline's treatment algorithm is not age specific since 1) the disease pathophysiology of prolonged seizures and status epilepticus and 2) anticonvulsant drug effects on neuronal receptors are the same from infants through adults, permitting a unified approach for all patients older than neonates. The following issues are not examined in this guideline: merits of various definitions of status epilepticus, treatment of refractory status epilepticus, treatment of neonatal status epilepticus, subsequent chronic anticonvulsant therapy, etiology-specific therapy (e.g., for cerebral malaria), the role of different diagnostic tests (e.g., EEG, CT, MRI) for patients with status epilepticus, the role of epilepsy surgery, neurostimulation, or the ketogenic diet in the treatment of patients with status epilepticus. There is an American Academy of Neurology practice parameter on the diagnostic evaluation of the child with status epilepticus (15).
The variability in anticonvulsant costs makes it difficult for this guideline to address or incorporate issues of cost-effectiveness and related economic analyses. However, it is recognized that cost and formulary availability are practical parameters modifying the selection of initial anticonvulsant therapy. This guideline should not be construed as rigid. Rather, therapy choice ultimately must include consideration of the individual patient's clinical data along with the local availability and cost feasibility of different treatment options.

Methods

The methodology used to construct the evidence-based portion of this guideline was based on elements of guideline development used by the American Academy of Neurology (http://www.aan.com/Guidelines/) and the International League Against Epilepsy. The methodology was specified before the searches were conducted. A literature search was performed, including MEDLINE and Current Contents, for relevant articles published between January 1940 and September 2014 (inclusive). In addition, the Cochrane Library (Database of Systematic Reviews, Central Register of Controlled Trials, Methodology Register, Database of Abstracts of Reviews of Effects, Health Technology Assessment Database, and NHS Economic Evaluation Database) was serially searched (last in April 2015). Studies were considered potentially relevant if they included the term “status epilepticus,” examined anticonvulsant efficacy, safety, tolerability, or mode of use, and were a randomized controlled trial (RCT), cohort study, case control study, observational study, case series, meta-analysis, or systematic review. All languages were included. No sex or age limits were imposed, but searches were limited to human subjects. No studies published only as abstracts were included. Articles were excluded from further analysis if they related to nonepilepsy uses of anticonvulsants or focused on basic anticonvulsant mechanisms.
Each potentially relevant study found through this search methodology was abstracted for specific data, which were placed in evidence tables for further analysis. The review panel consisted of a group of neurologists, neurology nurses, emergency medicine physicians, clinical pharmacists, methodologists, and neurocritical care physicians with experience in status epilepticus and anticonvulsants. Potentially relevant studies were evaluated for their class of evidence using criteria detailed in Table 1. The guideline's conclusions and recommendations were based on criteria detailed in Table 2. These tables integrate the United States Agency for Health Care and Policy Research (16) and the American Academy of Neurology scoring system (17). However, two major modifications to the scoring system were made owing to the ethical and logistic difficulties in conducting convulsive status epilepticus trials:
1) A 10% noninferiority margin between test drug and comparator drug was considered to be clinically appropriate for noninferiority analyses and failed superiority studies (Table 1).
2) Fewer class I or II studies were needed to reach a Level A or B recommendation than for other neurologic conditions because of the challenges in conducting randomized, controlled, double-blind, status epilepticus studies (Table 2).
Table 1. Rating of Articles
Class I: Prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population. The following are also required:
a.
No more than two primary outcomes specified
b.
Concealed allocation
c.
Exclusion/inclusion criteria clearly defined
d.
Relevant baseline characteristics presented and substantially equivalent between treatment groups, or appropriate statistical adjustment for differences
e.
Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) with numbers sufficiently low to have minimal potential for bias
f.
Demonstration of superiority in a superiority study design or demonstration of noninferiority using a 10% margin in a noninferiority design
Class II: A prospective, randomized, controlled clinical trial with masked outcome assessment that lacks one or two criteria a–e (see class I) or a prospective matched group cohort study in a representative population with masked outcome assessment that meets criteria a–e
Class III: All other controlled trials in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurements
Class IV: Evidence from uncontrolled studies, case series, case reports, or expert opinion
Table 2. Translation of Article Ratings to Conclusions and Recommendations
Translation of Evidence to Recommendation Conclusion and Recommendation
Level A rating:  
 One or more class I studies or two or more consistent class II studies
Conclusion, level A:
 Established as effective, ineffective, or harmful for the given condition in the specified population
Recommendation:
 Should be done or should not be done
Level B rating:  
One or more class II studies or three or more consistent class III studies
Conclusion, level B:
 Probably effective, ineffective, or harmful for the given condition in the specified population
Recommendation:
 Should be considered or should not be considered
Level C rating:  
Two or more consistent class III studies
Conclusion, level C:
 Possibly effective, ineffective, or harmful for the given condition in the specified population
Recommendation:
 May be considered or may not be considered
Level U:  
 Lack of studies meeting level A, B, or C designation
Conclusion, level U:
 Data inadequate or insufficient. Given current knowledge, treatment is unproven.
Recommendation:
 None
The analysis addressed five questions involving adults/children with seizures lasting more than 5 minutes:
Q1. Which anticonvulsants are efficacious as initial and subsequent therapy?
Q2. What adverse events are associated with anticonvulsant administration?
Q3. Which is the most effective benzodiazepine?
Q4. Is IV fosphenytoin more effective than IV phenytoin?
Q5. When does anticonvulsant efficacy drop significantly (i.e., after how many different anticonvulsants does status epilepticus become refractory)?
The completed evidence-based guidelines and algorithm were reviewed and approved by the American Epilepsy Society Guidelines Committee (members of which were not part of the writing group). It was also reviewed and commented on by the Council on Clinical Activities, whose comments were incorporated and subsequently approved. Following committee and council approval, it was submitted to the American Epilepsy Society Board; and after review, comments, and revisions, the guideline was approved prior to submission for publication.

Results

Article and Meta-Analysis/Systematic Review Identification

Four search strategies yielded the following results (all searches were performed for the time frame of January 1, 1940 through September 30, 2014). For Pubmed, the following terms were used:
1) Search—status epilepticus, Limits—humans (n = 6,953 articles);
2) Search—status epilepticus, Limits—humans, clinical trial, randomized controlled trial (n = 210 articles);
3) Search—status epilepticus AND ((clinical [Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]); Limits—humans (n = 3,101 articles);
4) Search—status epilepticus and systematic[sb]; Limits—humans (n = 159 articles).
Similar searches were performed on the other databases. These computerized searches were last performed on October 9, 2014. The resulting studies were reviewed for relevance. The reference lists of all included studies were reviewed to identify any additional relevant studies not identified by the above searches. In total, 38 relevant RCTs were identified. A search of the Cochrane Library yielded four additional completed and relevant published meta-analyses (18–21). Pharmaceutical companies provided requested additional information on three RCTs.

Q1. Which Anticonvulsants Are Efficacious as Initial and Subsequent Therapy?

Adult Studies

Nine RCTs (three class I [22–24], one class II [25], and five class III [26–30]) addressed the efficacy of initial therapy. The 1998 Veteran's Affairs status epilepticus study was a multi-center randomized comparison of four different IV treatments: lorazepam (0.1 mg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam plus phenytoin (n = 146), phenobarbital (n = 133), or phenytoin (n = 145). Differential anticonvulsant efficacy was found in overt status epilepticus where the four treatment arms had an overall difference p (= 0.02) for the primary outcome variable. Only one head-to-head comparison met the prespecified statistical significance difference: lorazepam was superior to phenytoin (p = 0.001). There was no difference on the intent to treat (ITT) analysis (22).
A second class I study in adults (older than 18 years) with status epilepticus was initiated outside the hospital by paramedics (23). In this 2001 study, patients were randomized to receive 2 mg IV lorazepam or 5 mg IV diazepam or IV placebo in the ambulance. The protocol allowed a repeat dose if the seizure continued after 4 minutes (for a maximum lorazepam dose of 4 mg and diazepam dose of 10 mg). For this study, status epilepticus was defined as continuous or repeated seizure for >5 minutes without recovery of consciousness. Overall, 205 patients were randomized (lorazepam, n = 66; diazepam, n = 68; placebo, n = 71). The treatment was deemed successful if the status epilepticus had terminated at the time of arrival in the emergency department. Both lorazepam and diazepam were superior to placebo: lorazepam (59.1%) > placebo (21.1%) (OR, 4.8; 95% CI: 1.9–13.0) and diazepam (42.6%) > placebo (21.1%) (OR, 2.3; 95% CI: 1.0–5.9) (23).
A third class I study, the 2012 RAMPART trial, was a multi-center, double-blind randomized noninferiority comparison of intramuscular (IM) midazolam (test drug) to IV lorazepam (comparator) in adults and children with status epilepticus (24). Dosing was standardized to 10 mg (5 mg in children weighing 13–40 kg) IM midazolam or 4 mg (2 mg in children weighing 13–40 kg) IV lorazepam. Status epilepticus was defined as convulsions persisting for longer than 5 minutes that were still occurring after paramedic arrival. Treatment success was defined as absence of seizures without additional rescue therapy at time of arrival in the emergency department, with a prespecified noninferiority margin of 10%. A total of 893 subjects (n = 748; aged 21 years or older) were randomized to either IM midazolam (n = 448) or IV lorazepam (n = 445). The primary efficacy endpoint was achieved in 73% of subjects in the IM midazolam group compared with 63% in the IV lorazepam group, resulting in an absolute difference between groups of 10% (95% CI: 4.0–16.1), not only meeting the prespecified noninferiority requirement but also demonstrating superiority of midazolam for both the per protocol and ITT analyses in patients without established IV access (24).
A 1983 class II study compared IV lorazepam 4 mg and IV diazepam 10 mg in adults with convulsive status epilepticus (defined as ≥3 GTC seizures in 1 hour or ≥2 in rapid succession), absence status epilepticus, or complex partial status epilepticus (25). The patients could receive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33) (25). Lorazepam was successful for 78% of subjects after one dose and 89% after two doses; diazepam was successful for 58% of subjects after one dose and 76% after two doses. The study found no statistically significant difference between lorazepam and diazepam in seizure cessation after one or two medication administrations.
The five open-label class III initial therapy RCTs examined the efficacy of IV valproic acid (n = 2) (26, 27), IV phenytoin (n = 2) (26, 27), IV phenobarbital (n = 1) (29), IV diazepam plus phenytoin (n = 1) (29), IV levetiracetam (n = 1) (30), rectal diazepam (n = 1) (28), and IV lorazepam (n = 1) (30) in cohorts ranging from 9 to 41 patients. Valproic acid had higher efficacy than phenytoin in one study (valproic acid, 66%, vs phenytoin, 42%; p = 0.046) (27) and was similar to phenytoin in the other (valproic acid, 87.8%, vs phenytoin, 88%) (26).
Two RCTs, both class III (31, 32), addressed second-therapy efficacy in adults after failure of initial benzodiazepine therapy. Intravenous valproic acid's efficacy was similar to IV phenytoin (88% vs 84%) in one study (31) and similar to continuous IV diazepam (56% vs 50%) in the second study (32).
Each arm of the Veterans Affairs status epilepticus study had a second blinded treatment if initial therapy was unsuccessful (22). Specifically, initial lorazepam therapy was followed by IV phenytoin; phenobarbital was followed by phenytoin; phenytoin was followed by lorazepam; and diazepam plus phenytoin was followed by lorazepam (22). There was no difference in efficacy between the four treatment arms when initial and second therapies together were examined (33).
The following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV lorazepam in adults with convulsive status epilepticus without established IV access (level A). Intravenous lorazepam is more effective than IV phenytoin in stopping seizures lasting at least 10 minutes (level A). There is no difference in efficacy between IV lorazepam followed by IV phenytoin, IV diazepam plus phenytoin followed by IV lorazepam, and IV phenobarbital followed by IV phenytoin (level A). Intravenous valproic acid has similar efficacy to IV phenytoin or continuous IV diazepam as second therapy after failure of a benzodiazepine (level C). Insufficient data exist in adults about the efficacy of levetiracetam as either initial or second therapy (level U).

Pediatric Studies

Overall, 26 RCTs (two class I [24, 34] and 24 class III [27, 30, 35–56]) examined efficacy of initial therapy. In 25 of these RCTs, benzodiazepines were one or both of the study medications (two class I studies and 23 class III studies). In one class I trial (34), 273 children (aged 3 months to 18 years) were enrolled and randomized to either diazepam 0.2 mg/kg (maximum dose 8 mg) or lorazepam 0.1 mg/kg (maximum dose 4 mg). If seizures continued after 5 more minutes, then half of the initial study drug dose could be repeated. If seizures continued another 7 more minutes, then fosphenytoin was given. There was no difference between IV diazepam (101/140, 72.1%) and IV lorazepam (97/133, 72.9%) in the primary efficacy outcome of termination of status epilepticus by 10 minutes without reappearance within 30 minutes (absolute difference of 0.8%, 95% CI: −11.4–9.8%). The study concluded that there was no evidence to support the hypothesis that lorazepam was superior to diazepam as initial therapy for pediatric status epilepticus.
A second class I study, the RAMPART trial (24), included 120 children randomized to IM midazolam (n = 60) or IV lorazepam (n = 60). No statistical difference in efficacy was found between the IM midazolam (68.3%) and IV lorazepam (71.7%), but the relatively few children studied results in wide confidence intervals preventing any firm conclusions (57).
The class III benzodiazepine RCTs involved diazepam (n = 20), midazolam (n = 16), and lorazepam (n = 6). The different routes of administration included IV (n = 13), rectal (n = 10), intranasal (n = 9), buccal (n = 6), IM (n = 3), and sublingual (n = 1). The size of the studies ranged from 24 patients to 436 patients. Although all studies were prospective and randomized, they were class III because treating physicians were either not blinded to treatment allocation or lacked outcome masking (meaning the outcome assessors were not blinded to treatment allocation).
One class III study compared lorazepam (0.05–0.1 mg/kg) to diazepam (0.3–0.4 mg/kg) administered either IV or rectally for children presenting to the emergency department with ongoing convulsions. There was no difference between the treatments either in the time for the initial (presenting) seizure to stop after anticonvulsant administration or in the total number of seizures in first 24 hours of admission. However, fewer lorazepam patients required multiple doses to stop the seizures (lorazepam 8/33 vs diazepam 25/53; p < 0.05) or additional anticonvulsants to terminate the seizure (lorazepam 1/33 vs diazepam 17/53; p < 0.01) (35).
One class III study compared IV lorazepam (0.1 mg/kg) to a combination of IV diazepam (0.2 mg/kg) and IV phenytoin (18 mg/kg) in 178 children presenting with convulsive status epilepticus to an emergency department. Efficacy in stopping seizure activity within 10 minutes with no recurrence during an 18-hour period after seizure control was 100% for both groups. No significant difference was demonstrated between treatment groups either in the time to seizure cessation or the need for additional doses of study medication to terminate convulsive status epilepticus (49).
Intranasal lorazepam was examined in two studies. A study of 6- to 14-year-old children with ongoing seizures in the emergency department compared IV lorazepam with intranasal lorazepam (both 0.1 mg/kg/dose, maximum dose 4 mg) (52). No difference was detected between IV lorazepam (56/70, 80%) and intranasal lorazepam (59/71, 83.1%) based on clinical seizure remission within 10 minutes of study drug administration. The authors concluded that intranasal lorazepam was not inferior to IV lorazepam (52). Another class III study compared intranasal lorazepam (0.1 mg/kg) to IM paraldehyde (0.2 mL/kg) in 160 pediatric patients presenting to an emergency department with convulsive status epilepticus. No statistically significant difference was found between intranasal lorazepam and IM paraldehyde for the primary outcome of efficacy in stopping seizure activity 10 minutes after administration (intranasal lorazepam, 75%; IM paraldehyde, 61%; p = 0.06) or in time to seizure cessation or seizure recurrence within 24 hours after administration. The study did find that subjects treated with paraldehyde were more likely to require two or more additional anticonvulsant doses (intranasal lorazepam, 10%; IM paraldehyde, 26%; p = 0.007) (44).
Sublingual lorazepam (0.1 mg/kg) was compared with rectal diazepam (0.5 mg/kg) in children 5 months to 10 years old with convulsions lasting more than 5 minutes (54). This class III RCT was conducted across nine hospitals in Sub-Saharan Africa and involved 436 children. The efficacy of sublingual lorazepam (131/234, 56%) was significantly lower than that for rectal diazepam (160/202, 79%; p < 0.001) for terminating seizures within 10 minutes of study drug administration (54).
Sixteen class III studies compared midazolam with diazepam. In five studies, buccal midazolam was compared with rectal diazepam (40–42, 47, 50). In one study, in 177 children experiencing 219 separate seizures, buccal midazolam was more effective than rectal diazepam in stopping seizures whether all seizures were considered (56% vs 27%) or just initial episodes (42). The largest study of 330 children in Uganda found a lower rate of treatment failure (seizures lasting longer than 10 minutes after medication administration or seizure recurrence within 1 hour) for buccal midazolam compared with rectal diazepam (30.3% vs 43%; p = 0.016). This superiority was limited to a subgroup of patients without malaria, with buccal midazolam superior to rectal diazepam with respect to treatment failure (26.2% vs 55.9%; p = 0.002) (47). In an RCT of 98 children (aged 3 months to 12 years), buccal midazolam was superior to rectal diazepam for control of seizures within 5 minutes of administration (49/49, 100%, vs 40/49, 82%; p < 0.001), treatment initiation time (median 2 vs 3 minutes; p < 0.001), and drug effect time (median 4 vs 5 minutes; p < 0.001) (50). In the two smaller studies (n = 79 and n = 43), there was no difference in efficacy between buccal midazolam and rectal diazepam (40, 41).
Intranasal midazolam was compared with IV diazepam in four class III pediatric studies (38, 39, 46, 53). In one study involving children with prolonged febrile seizures, time to drug administration of intranasal midazolam was faster (p < 0.001) but the time period between drug administration and seizure cessation was shorter for IV diazepam (p < 0.001) (38). The second study found that the mean time to achieve seizure control was faster for IV diazepam compared with intranasal midazolam (p < 0.007) (39). A third study found intranasal midazolam was significantly faster to administer than IV diazepam, with a slower mean time to seizure cessation after medication administration for intranasal midazolam compared with IV diazepam, but a faster time to seizure cessation after hospital arrival with intranasal midazolam (p < 0.001 for all comparisons) (46). Lastly, an RCT of 60 children (aged 2 months to 15 years), equally divided between intranasal midazolam (0.2 mg/kg) and IV diazepam (0.3 mg/kg), found the time to control seizures was shorter using intranasal midazolam compared with IV diazepam (3.16 ± 1.24 minutes vs 6.42 ± 2.59 minutes; p < 0.001) when the time needed to establish IV access was included (53).
Three trials examined the efficacy of intranasal midazolam compared with rectal diazepam (37, 45, 51). Intranasal midazolam (0.2 mg/kg, maximum dose, 10 mg) was compared with rectal diazepam (0.3 to 0.5 mg/kg, maximum dose, 20 mg) for prehospital seizures lasting longer than 5 minutes. Overall, 92 children received study medication, and no difference in total seizure time after medication administration between therapies was identified (51). Another trial involving 46 children experiencing 188 seizures compared the efficacy of intranasal midazolam 0.3 mg/kg (92 episodes) to rectal diazepam 0.2 mg/kg (96 episodes) for terminating seizures within 10 minutes of drug administration. The time to seizure cessation was significantly faster for intranasal midazolam (116.7 ± 126.9 seconds vs 178.6 ± 179.5 seconds; p = 0.005), with a trend toward a higher success rate with intranasal midazolam (89/92, 96.7%) compared with rectal diazepam (85/96, 88.5%; p = 0.060) (45). A third smaller trial (n = 45) found intranasal midazolam was more effective than rectal diazepam (87% vs 60%; p < 0.05) (37).
Intramuscular midazolam was compared with IV diazepam in three class III studies (36, 43, 55). In all three studies, IM midazolam had a shorter interval to seizure cessation, but there was no significant difference in overall efficacy for termination of seizures (36, 43, 55).
One study compared buccal midazolam 0.2 mg/kg with IV diazepam 0.3 mg/kg, with no significant difference found in overall efficacy (defined as complete cessation of seizures 5 minutes after administration of study treatment) (48). Time to seizure cessation from identification of the seizure in the emergency department was significantly shorter for buccal midazolam compared with IV diazepam (2.39 minutes vs 2.98 minutes, respectively), with most of the difference driven by more rapid time to initiation of treatment (48).
Intravenous lorazepam (0.1 mg/kg over 2–4 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus (30). As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for levetiracetam (31/41, 75.6%) (30).
In one RCT, children with convulsive seizures at time of presentation received either IV valproic acid (20 mg/kg) with diazepam (0.3 mg/kg) (n = 16) or IV phenytoin (20 mg/kg) with diazepam (0.3 mg/kg) (n = 17) (56). There was no difference in efficacy outcomes between these two arms (56).
The only class III pediatric RCT not involving a benzodiazepine compared IV phenytoin (n = 33) and IV valproic acid (n = 35). Overall, valproic acid had higher efficacy than phenytoin (valproic acid, 66%, vs phenytoin, 42%; p = 0.046), but only 23% and 12% of the cohorts were 15 years old or younger, with no statistical adjustment for these dissimilar proportions (27).
Two RCTs (one class II [58] and one class III [31]) addressed second-therapy efficacy in children after failure of initial benzodiazepine therapy. The class II study compared IV valproic acid (20 mg/kg, n = 30) with IV phenobarbital (20 mg/kg, n = 30) in children 3 to 16 years old whose seizures did not respond to IV diazepam (0.2 mg/kg) within 5 minutes. No significant difference was noted in efficacy between valproic acid and phenobarbital (27/30, 90%, vs 23/30, 77%; p = 0.189) for terminating seizures within 20 minutes, but the valproic acid group experienced significantly fewer clinically significant adverse effects (24% vs 74%; p < 0.001) (58). The second study involved both adults and children and found that the efficacy of IV valproic acid was similar to that of IV phenytoin (88% vs 84%) in patients whose seizures did not respond to 0.2 mg/kg of IV diazepam (31).
The following conclusions were drawn. In children, IV lorazepam and IV diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Rectal diazepam, IM midazolam, intranasal midazolam, and buccal midazolam are probably effective at stopping seizures lasting at least 5 minutes (level B). Insufficient data exist in children about the efficacy of intranasal lorazepam, sublingual lorazepam, rectal lorazepam, valproic acid, levetiracetam, phenobarbital, and phenytoin as initial therapy (level U). Intravenous valproic acid has similar efficacy but better tolerability than IV phenobarbital (level B) as second therapy after failure of a benzodiazepine. Insufficient data exist in children regarding the efficacy of phenytoin or levetiracetam as second therapy after failure of a benzodiazepine (level U).

Q2. What Adverse Events Are Associated with Anticonvulsant Administration?

Adult Studies

Three class I studies (22–24) and one class II study (25) present the best evidence about treatment-emergent adverse events associated with IV lorazepam and diazepam therapy. In the 1998 class I Veterans Affairs status epilepticus study, there were no significant differences in adverse-event rates between lorazepam, diazepam, phenobarbital, and phenytoin (22). The treatment-emergent adverse events associated with lorazepam administration in 97 patients with overt status epilepticus were hypoventilation, 10.3%; hypotension, 25.8%; and cardiac rhythm disturbance, 7.2%. This is similar to the adverse events seen with IV diazepam therapy in 95 patients with overt status epilepticus: hypoventilation, 16.8%; hypotension, 31.6%; and cardiac rhythm disturbance, 2.1%. A similar spectrum of cardiorespiratory complications was seen in both the phenobarbital arm (hypoventilation, 13.2%; hypotension, 34.1%; cardiac rhythm disturbance, 3.3%) and the phenytoin arm (hypoventilation, 9.9%; hypotension, 27.0%; cardiac rhythm disturbance, 6.9%) (22).
In the 2001 prehospital status epilepticus RCT, 10.6% of patients receiving IV lorazepam experienced treatment-emergent adverse events (hypotension, cardiac dysrhythmia, respiratory intervention). Similarly, 10.3% of patients receiving IV diazepam experienced hypotension, cardiac dysrhythmia, or the need for respiratory intervention. Both of these rates were lower (p = 0.08) than the 22.5% treatment-emergent adverse-event rate seen in patients with status epilepticus receiving IV placebo (23).
In the 2012 class I RAMPART trial comparing IM midazolam and IV lorazepam (24), treatment-emergent adverse events were identified in 26.7% of subjects in the IM midazolam group compared with 30.6% of subjects in the IV lorazepam group. Most common treatment-emergent adverse events were decreased level of consciousness (IM midazolam, 9.5%, vs IV lorazepam, 8.8%) and respiratory depression (IM midazolam, 6.4%, vs IV lorazepam, 10%), while hypotension only occurred in 1.2% of subjects overall (24).
The 1983 class II study compared lorazepam 4 mg and diazepam 10 mg in adults with convulsive status epilepticus (defined as ≥3 GTC seizures in 1 hour or ≥2 in rapid succession), absence status epilepticus, or complex partial status epilepticus (25). Patients were permitted to receive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33). In this comparative trial, 12% of lorazepam patients and 13% of diazepam patients experienced treatment-emergent adverse events including respiratory depression, respiratory arrest, hypotension, and sedation; the first three of these only occurred in people with significant medical problems (25).
The following conclusions were drawn. Respiratory and cardiac symptoms are the most common encountered treatment-emergent adverse events associated with IV anticonvulsant administration in adults with status epilepticus (level A). The rate of respiratory depression in patients with status epilepticus treated with benzodiazepines is lower than in patients with status epilepticus treated with placebo (level A), indicating that respiratory problems are an important consequence of untreated status epilepticus. No substantial difference exists between benzodiazepines and phenobarbital in the occurrence of cardiorespiratory adverse events in adults with status epilepticus (level A).

Pediatric Studies

The single class I purely pediatric study (34) provides the best adverse-event evidence about IV lorazepam and IV diazepam use in children with convulsive status epilepticus. There were no differences between the two arms in the rate of assisted ventilation (lorazepam, 17.6%, versus diazepam, 16.0%; absolute risk difference, 1.6%; 95% CI: −9.9–6.8%) or aspiration pneumonia (two subjects in each group). The incidence of sedation was higher in the lorazepam cohort (99/148, 66.9%) compared with the diazepam cohort (81/162, 50%; absolute risk difference, 16.9%; 95% CI: 6.1–27.7%) (34).
Class III trials identified similar rates of respiratory depression with IV benzodiazepine use (35, 49, 55). One class III trial reported 21% of patients receiving IV diazepam and 4% of patients receiving IV lorazepam were reported to have respiratory depression defined as poor respiratory effort, reduced rate of breathing, or requiring oxygen administration via face mask (35). In another class III study, respiratory depression was reported in 4.4% of children receiving IV lorazepam and 5.6% of children receiving IV diazepam and phenytoin, but no subject in either group required mechanical ventilation (49).
Respiratory depression after rectal administration of diazepam in children was reported in five class III trials, ranging from 1.2 percent to 6.4 percent (35, 41, 42, 45, 47), while two class III trials (37, 40) and two class I trials in acute repetitive seizures (59, 60) reported no incidence of respiratory depression with rectal diazepam use in children. No respiratory depression was reported in one study of six children treated with rectal lorazepam (35). As noted above, drowsiness was the most common adverse effect reported in two class I trials of rectal diazepam in a mixed adult and pediatric study (59, 60).
Two class III studies reported respiratory depression with use of buccal midazolam in children (42, 47), in contrast to two class III studies, which reported no respiratory depression associated with use of buccal midazolam in the pediatric population (40, 41). Respiratory depression, defined as having a need for assisted ventilation because of a drop in oxygen saturation or a reduction in respiratory rate or effort, was reported in 1.2% and 4.6% of patients in these studies (42, 47). Two of the class III IM or intranasal midazolam studies reported significant respiratory depression (36–39, 43, 45, 46, 53). Single children in each study (6.25% and 2%) in the IM midazolam group experienced respiratory failure resulting in artificial ventilation (51, 55).
Two class III studies involved intranasal lorazepam. In one study of 80 children, a drop of ≥5 mm Hg in systolic and diastolic blood pressure was noted in 15 (18.8%) and 12 (15%) children, respectively, while only two (2.5%) had a fall in oxygen saturation below 92% (44). In a second study of 71 children, none developed significant hypotension and only one (1.4%) required assisted ventilation (52).
The following conclusions were drawn. Respiratory depression is the most common clinically significant treatment-emergent adverse event associated with anticonvulsant drug treatment in status epilepticus in children (level A). No substantial difference probably exists between midazolam, lorazepam, and diazepam administration by any route in children with respect to rates of respiratory depression (level B). Adverse events, including respiratory depression, with benzodiazepine administration for status epilepticus have been reported less frequently in children than in adults (level B).

Q3. Which is the Most Effective Benzodiazepine?

Adult Studies

In a class I prehospital status epilepticus study (23), the percentage of patients’ status epilepticus stopped by lorazepam was higher but not significantly different than with diazepam (odds ratio [OR], 1.9; 95% CI: 0.8–4.4). However, the study's sample size was selected to be able to detect a difference between the active drugs and placebo, not to detect a difference between the two active drugs (23). In a class II lorazepam–diazepam comparative trial (25), there was no difference between the two arms in the percentage of patients having control of seizures after either one injection (lorazepam, 78%; diazepam, 58%; not significant [NS]) or two injections (lorazepam, 89%; diazepam, 76%; NS). There was no significant difference between the two arms in the latency of action (lorazepam median, 3 minutes; diazepam median, 2 minutes; NS) (25).
The class I RAMPART trial (24) reported seizures were absent in 73% of subjects in the IM midazolam group compared with 63% in the IV lorazepam group, resulting in an absolute difference of 10% (95% CI: 4.0–16.1; p < 0.001) that met the prespecified noninferiority requirements plus additional superiority for both per protocol and ITT analyses. Median time from active treatment to cessation of convulsions was shorter for IV lorazepam (1.6 minutes) compared with IM midazolam (3.3 minutes), which was offset by more rapid IM midazolam administration (IV lorazepam, 4.8 minutes, vs intranasal midazolam, 1.2 minutes) (24).
There is no difference in the treatment-emergent adverse-event profiles between lorazepam and diazepam in the three adult class I and class II status epilepticus studies (22, 23, 25). No differences in treatment-emergent adverse-event profiles were found between IM midazolam and IV lorazepam (24). There is pharmacokinetic evidence to suggest a longer duration of action (but not longer half-life) for lorazepam compared with diazepam (61).
The following conclusions were drawn. In adults with status epilepticus without established IV access, IM midazolam is established as more effective compared with IV lorazepam (level A). No significant difference in effectiveness has been demonstrated between lorazepam and diazepam in adults with status epilepticus (level A).

Pediatric Studies

As described in detail in Question 1, one class I trial enrolled and randomized 273 children to either IV diazepam or IV lorazepam (34). Efficacy was similar between IV diazepam (101/140, 72.1%) and IV lorazepam (97/133, 72.9%). As described in detail in Question 2, side-effect profiles of the two treatments were similar (34).
A meta-analysis of six class III pediatric studies (36, 38–40, 42, 47) found non-IV midazolam (IM/intranasal/buccal) was more effective than diazepam (IV/rectal) at achieving seizure cessation (relative risk [RR] =1.52, 95% CI: 1.27–1.82) with similar respiratory complications (RR = 1.49; 95% CI: 0.25–8.72) (62). Time to seizure cessation was shorter for intranasal midazolam compared with IV diazepam in two studies (38, 46) and longer in one study (39). Comparing intranasal midazolam and rectal diazepam, intranasal midazolam was more effective in terminating seizures (37) and demonstrated a shorter time to seizure termination (45). Comparing IM midazolam to IV diazepam, a shorter interval to seizure cessation was found for IM midazolam in both studies (36, 43). Only one study found a significantly shorter time to seizure cessation for buccal midazolam compared with rectal diazepam (42).
One study comparing lorazepam to diazepam found no difference between the treatments in the time for the initial (presenting) seizure to stop after anticonvulsant administration but did find fewer lorazepam patients required multiple doses (lorazepam, 8/33, vs diazepam, 25/53; p < 0.05) or additional anticonvulsants (lorazepam, 1/33, vs diazepam, 17/53; p < 0.01) for seizure cessation (35).
The following conclusions were drawn. In children with status epilepticus, no significant difference in effectiveness has been established between IV lorazepam and IV diazepam (level A). In children with status epilepticus, non-IV midazolam (IM/intranasal/buccal) is probably more effective than diazepam (IV/rectal) (level B).

Q4. is IV Fosphenytoin More Effective than IV Phenytoin?

Three class III RCTs examined the comparative tolerability of IV fosphenytoin and IV phenytoin (63). A single-dose, randomized, double-blind, class III tolerability study in patients needing infusion of phenytoin compared fosphenytoin (n = 39, 12.7 mg/kg, 82 mg phenytoin equivalent [PE]/min [range, 40–103 mg PE/min]) to phenytoin (n = 13, 11.3 mg/kg, 42.4 mg/min). In contrast to phenytoin, there were no fosphenytoin-related significant cardiac arrhythmias, change in heart rate, respiration or blood pressure (63). A second study involved patients requiring a phenytoin loading dose and then 3 to 14 days of maintenance therapy. This randomized, double-blind, class III tolerability study in patients needing infusion and maintenance of phenytoin compared fosphenytoin (n = 88, 15.3 mg/kg, 37 mg PE/min) to phenytoin (n = 28, 15.0 mg/kg, 33 mg/min) and found pain at the infusion site was greater for phenytoin than fosphenytoin (17% vs 2%) (63) A third study was a single-dose, randomized, double-blind, class III tolerability study of fosphenytoin at 150 mg PE/min (n = 90) vs phenytoin at 50 mg/min (n = 22) (63). The infusion was slowed or discontinued more often with IV phenytoin compared with IV fosphenytoin; 63.6% of phenytoin patients experienced pain at site of infusion; 48.6% of fosphenytoin patients encountered pruritus; and the average blood pressure decrease with fosphenytoin was 13.7 mm Hg compared with 5.9 mm Hg with phenytoin.
The following conclusions were drawn. Insufficient data exist about the comparative efficacy of phenytoin and fosphenytoin (level U). Fosphenytoin is better tolerated compared with phenytoin (level B). When both are available, fosphenytoin is preferred based on tolerability, but phenytoin is an acceptable alternative (level B).

Q5. When Does Anticonvulsant Efficacy Drop Significantly (i.e., after how Many Different Anticonvulsants Does Status Epilepticus Become Refractory)?

Only one class I RCT (the Veterans Affairs status epilepticus trial) (22) provides clear data to address this question. Treatment success was defined as status epilepticus stopping within 20 minutes after infusion started with no recurrence prior to 60 minutes after the start of the infusion. In this four-arm double-blind RCT, in order to maintain the blinding, if the first administered anticonvulsant was not successful, then the patient was randomized to another treatment arm; if the second anticonvulsant was not successful, then the patient was randomized to another treatment arm. In adults with overt status epilepticus, the overall success rate of the first administered therapy was 55.5%. If the first study drug did not succeed, the second study drug was able to stop the status epilepticus for an additional 7.0% of the total population; the third drug helped only an additional 2.3% of patients. It took intensive “non-study” therapy to stop the status epilepticus in 23.2% of the initial patient population, and no drug was successful within 12 hours in 11.7%. In this study, if the patient did not respond to lorazepam or phenytoin, the response rate to phenobarbital was 2.1% (D. Treiman, verbal communication).
Three other RCTs (31, 32, 58), detailed earlier, reported higher rates of second-therapy efficacy in adults and children after failure of initial benzodiazepine therapy. However, in each of these studies, initial therapy was not part of an RCT nor was it blinded. For second therapy, the class II RCTs reported success ranging from 77 percent to 90 percent, while the two class III RCTs reported success ranging from 50 percent to 88 percent.
The following conclusions were drawn. In adults, the second anticonvulsant administered is less effective than the first “standard” anticonvulsant, while the third anticonvulsant administered is substantially less effective than the first “standard” anticonvulsant (level A). In children, the second anticonvulsant appears less effective, and there are no data about third anticonvulsant efficacy (level C).

Recommendations and Algorithm

Based on the evidence-based answers to the above questions, a treatment algorithm is proposed for convulsive status epilepticus (Figure 1). As stated earlier, clinical trials have arbitrarily focused on either adults or children, and only three trials (24, 27, 30) included both. The guideline's treatment algorithm is not age specific because the disease pathophysiology of prolonged seizures/status epilepticus and anticonvulsant drug effects on neuronal receptors are the same from infants through adults, permitting a unified approach for all patients older than neonates.
Figure 1. Proposed treatment algorithm for status epilepticus.
Disclaimer: This clinical algorithm/guideline is designed to assist clinicians by providing an analytical framework for evaluating and treating patients with status epilepticus. It is not intended to establish a community standard of care, replace a clinician's medical judgment, or establish a protocol for all patients. The clinical conditions contemplated by this algorithm/guideline will not fit or work with all patients. Approaches not covered in this algorithm/guideline may be appropriate.
The algorithm starts with a stabilization phase (0–5 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy should be apparent. A benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice, given their demonstrated efficacy, safety, and tolerability (level A, four class I RCTs). Although IV phenobarbital is established as efficacious and well tolerated as initial therapy (level A, 1 class I RCT), its slower rate of administration, compared with the three recommended benzodiazepines above, positions it as an alternative initial therapy rather than a drug of first choice. For prehospital settings or where the three first-line benzodiazepine options are not available, rectal diazepam, intranasal midazolam, and buccal midazolam are reasonable initial therapy alternatives (level B). Initial therapy should be administered as an adequate single full dose rather than broken into multiple smaller doses. Initial therapies should not be given twice except for IV lorazepam and diazepam that can be repeated at full doses once (level A, two class I, one class II RCT). Doses listed in the initial therapy phase are those used in class I trials. Note that some consensus guidelines list slightly different dosages; for example, phenobarbital is often recommended at 20 mg/kg (2).
The second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study) and levetiracetam (level U). There is no clear evidence that any one of these options is better than the others. The ongoing Established Status Epilepticus Treatment Trial (ESETT) should provide the answer in the next few years (64). Because of adverse events, IV phenobarbital is a reasonable second-therapy alternative (level B, one class II study) if none of the three recommended therapies are available.
The third therapy phase should begin when the seizure duration reaches 40 minutes. There is no clear evidence to guide therapy in this phase (level U). Compared with initial therapy, second therapy is often less effective (adults—level A, one class I RCT; children—level C, two class III RCTs), and the third therapy is substantially less effective (adults—level A, one class I RCT; children—level U) than initial therapy. Thus, if second therapy fails to stop the seizures, treatment considerations should include repeating second-line therapy or anesthetic doses of either thiopental, midazolam, pentobarbital, or propofol (all with continuous EEG monitoring). Depending on the etiology or severity of the seizure, patients may go through the phases faster or even skip the second phase and move rapidly to the third phase, especially in sick or intensive care unit patients. The evidence-based treatment of refractory status epilepticus is beyond the scope of this guideline, though others have addressed the issue (65).

Future Directions

Additional evidence to further define the role of other IV-administered anticonvulsants is crucial to future treatment of convulsive status epilepticus. Class III trials support efficacy and safety of valproic acid as first-line therapy (26, 27), second-line therapy (31, 32), and refractory therapy (66). Evidence for use of levetiracetam and lacosamide is limited to retrospective studies (67–72). Given the favorable pharmacokinetic characteristics and adverse-effect profiles for these medications compared with fosphenytoin and phenobarbital, comparative trials of these medications as second-line therapy will provide vital evidence to improve future treatment of convulsive status epilepticus. The current National Institute of Neurological Disorders and Stroke funded ESETT trial compares IV fosphenytoin, levetiracetam, and valproate in children and adults with status epilepticus who did not respond to initial benzodiazepine therapy. ESETT is designed to be a class I RCT that will identify the optimal second therapy for benzodiazepine-resistant status epilepticus (64).

Disclosures

Drs. Glauser, Alldredge, Arya, Bleck, Dodson, Garrity, Riviello, Sloan, and Treiman, along with Ms. Bare, have nothing to disclose relevant to this guideline. Dr. Shinnar serves on a Data Safety Monitoring Board (DSMB) for a UCB Pharma clinical trial of a non–epilepsy-related drug. Dr. Gloss is an evidence-based methodologist of the American Academy of Neurology, a level-of-evidence associate editor of Neurology, and has no disclosures relevant to this guideline. Dr. Bainbridge receives grant funding from UCB Pharma for a study in the elderly. Dr. Lowenstein is a principal investigator of the Human Epilepsy Project (HEP), which is supported by unrestricted grants to the Epilepsy Study Consortium from UCB Pharma, Finding A Cure for Epilepsy and Seizures, Pfizer, Eisai, Lundbeck, and The Andrews Foundation. The funding is for a study unrelated to status epilepticus. Dr. Pellock is a paid consultant for two companies (Pfizer and UCB). All grants, research support, consultant fees, and honoraria are paid to Virginia Commonwealth University or the physician practice plan (MCV Physicians). Dr. Pellock has no equity, stock, or any other ownership interest in either of these companies. Dr. Jagoda is a paid consultant for Pfizer, TEVA, and The Medicines Company for diseases unrelated to status epilepticus.
Added during proofs: While the AES guideline was developed prior to the ILAE's revised definition of status epilepticus (Trinka et al., Epilepsia 2015;56:1515–1523), the 5 minute definition used in this guideline is fully consistent with the operational 5 minute time point (t1) for treatment initiation for convulsive status epilepticus proposed in that document.

References

1. Glauser TA. Designing practical evidence-based treatment plans for children with prolonged seizures and status epilepticus. J Child Neurol 2007; 22(suppl 5): 38S–46S.
Crossref
Google Scholar
2. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270: 854–859.
Crossref
ISI
Google Scholar
3. Shinnar S Berg AT Moshe SL Shinnar R. How long do new-onset seizures in children last? Ann Neurol 2001; 49: 659–664.
Crossref
ISI
Google Scholar
4. Raspall-Chaure M Chin RF Neville BG Bedford H Scott RC. The epidemiology of convulsive status epilepticus in children: A critical review. Epilepsia 2007; 48: 1652–1663.
Crossref
Google Scholar
5. DeLorenzo RJ Hauser WA Towne AR Boggs JG Pellock JM Penberthy L Garnett L Fortner CA Ko D. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46: 1029–1035.
Crossref
ISI
Google Scholar
6. Wu YW Shek DW Garcia PA Zhao S Johnston SC. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002; 58: 1070–1076.
Crossref
ISI
Google Scholar
7. Hauser WA. Status epilepticus: Epidemiologic considerations. Neurology 1990; 40: 9–13.
ISI
Google Scholar
8. Maytal J Shinnar S Moshe SL Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989; 83: 323–331.
Crossref
ISI
Google Scholar
9. Jagoda A Riggio S. Refractory status epilepticus in adults. Ann Emerg Med 1993; 22: 1337–1348.
Crossref
ISI
Google Scholar
10. Logroscino G Hesdorffer DC Cascino GD Annegers JF Bagiella E Hauser WA. Long-term mortality after a first episode of status epilepticus. Neurology 2002; 58: 537–541.
Crossref
Google Scholar
11. DeLorenzo RJ Towne AR Pellock JM Ko D. Status epilepticus in children, adults, and the elderly. Epilepsia 1992; 33(suppl 4): S15–S25.
Crossref
Google Scholar
12. Neligan A Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: A review. Epilepsy Res 2011; 93: 1–10.
Crossref
ISI
Google Scholar
13. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998; 39: 799–803.
Crossref
ISI
Google Scholar
14. Chadwick D. Monotherapy clinical trials of new antiepileptic drugs: Design, indications, and controversies. Epilepsia 1997; 38(suppl 9): S16–S20.
Crossref
Google Scholar
15. Riviello JJ Jr, Ashwal S Hirtz D Glauser T Ballaban-Gil K Kelley K Morton LD Phillips S Sloan E Shinnar S; American Academy of Neurology Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: Diagnostic assessment of the child with status epilepticus (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2006; 67: 1542–1550.
Crossref
ISI
Google Scholar
16. Agency for Healthcare Policy and Research UDoHaHS. Acute pain management: Operative or medical procedures and trauma. In: Clinical Practice Guideline No 1. Rockville, MD: Agency for Healthcare Policy and Research, 1993: 107.
Google Scholar
17. Edlund W Gronseth G So Y Franklin G; for the Quality Standards Subcommittee (QSS) and the Therapeutics and Technology Assessment Subcommittee (TTA). American Academy of Neurology Clinical Practice Guideline Process Manual. St. Paul, MN: American Academy of Neurology, 2004.
Google Scholar
18. Prasad M Krishnan PR Sequeira R Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2014; 9: CD003723. doi:10.1002/14651858.CD003723.pub3.
Crossref
Google Scholar
19. Appleton R Macleod S Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2008; 3: CD001905. doi:10.1002/14651858.CD001905.pub2.
Crossref
Google Scholar
20. Prasad K Al-Roomi K Krishnan PR Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2005;Oct 19;(4): CD003723 PMID:16235337.
Google Scholar
21. Appleton R Martland T Phillips B. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2002;(4): CD001905. PMID:12519562
Google Scholar
22. Treiman DM Meyers PD Walton NY Collins JF Colling C Rowan AJ Handforth A Faught E Calabrese VP Uthman BM Ramsay RE Mamdani MB. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792–798.
Crossref
ISI
Google Scholar
23. Alldredge BK Gelb AM Isaacs SM Corry MD Allen F Ulrich S Gottwald MD O'Neil N Neuhaus JM Segal MR Lowenstein DH. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345: 631–637.
Crossref
ISI
Google Scholar
24. Silbergleit R Durkalski V Lowenstein D Conwit R Pancioli A Palesch Y Barsan W; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366: 591–600.
Crossref
ISI
Google Scholar
25. Leppik IE Derivan AT Homan RW Walker J Ramsay RE Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249: 1452–1454.
Crossref
ISI
Google Scholar
26. Gilad R Izkovitz N Dabby R Rapoport A Sadeh M Weller B Lampl Y. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008; 118: 296–300.
Crossref
Google Scholar
27. Misra UK Kalita J Patel R. Sodium valproate vs phenytoin in status epilepticus: A pilot study. Neurology 2006; 67: 340–342.
Crossref
ISI
Google Scholar
28. Remy C Jourdil N Villemain D Favel P Genton P. Intrarectal diazepam in epileptic adults. Epilepsia 1992; 33: 353–358.
Crossref
ISI
Google Scholar
29. Shaner DM McCurdy SA Herring MO Gabor AJ. Treatment of status epilepticus: A prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988; 38: 202–207.
Crossref
ISI
Google Scholar
30. Misra UK Kalita J Maurya PK. Levetiracetam versus lorazepam in status epilepticus: A randomized, open labeled pilot study. J Neurol 2012; 259: 645–648.
Crossref
ISI
Google Scholar
31. Agarwal P Kumar N Chandra R Gupta G Antony AR Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007; 16: 527–532.
Crossref
ISI
Google Scholar
32. Chen WB Gao R Su YY Zhao JW Zhang YZ Wang L Ren Y Fan CQ. Valproate versus diazepam for generalized convulsive status epilepticus: A pilot study. Eur J Neurol 2011; 18: 1391–1396.
Crossref
Google Scholar
33. Treiman DM Walton N Collins JF Point P. Treatment of status epilepticus if first drug fails. Epilepsia 1999; 40: 153–156.
Google Scholar
34. Chamberlain JM Okada P Holsti M Mahajan P Brown KM Vance C Gonzalez V Lichenstein R Stanley R Brousseau DC Grubenhoff J Zemek R Johnson DW Clemons TE Baren J; Pediatric Emergency Care Applied Research Network (PECARN). Lorazepam vs diazepam for pediatric status epilepticus: A randomized clinical trial. JAMA 2014; 311: 1652–1660.
Crossref
ISI
Google Scholar
35. Appleton R Sweeney A Choonara I Robson J Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995; 37: 682–688.
Crossref
ISI
Google Scholar
36. Chamberlain JM Altieri MA Futterman C Young GM Ochsenschlager DW Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997; 13: 92–94.
Crossref
ISI
Google Scholar
37. Fisgin T Gurer Y Tezic T Senbil N Zorlu P Okuyaz C Akgün D. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: Prospective randomized study. J Child Neurol 2002; 17: 123–126.
Crossref
ISI
Google Scholar
38. Lahat E Goldman M Barr J Bistritzer T Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: Prospective randomised study. BMJ 2000; 321: 83–86.
Crossref
Google Scholar
39. Mahmoudian T Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004; 5: 253–255.
Crossref
ISI
Google Scholar
40. Scott RC Besag FM Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: A randomised trial. Lancet 1999; 353: 623–626.
Crossref
ISI
Google Scholar
41. Baysun S Aydin OF Atmaca E Gurer YK. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila) 2005; 44: 771–776.
Crossref
ISI
Google Scholar
42. McIntyre J Robertson S Norris E Appleton R Whitehouse WP Phillips B Martland T Berry K Collier J Smith S Choonara I. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: A randomised controlled trial. Lancet 2005; 366: 205–210.
Crossref
ISI
Google Scholar
43. Shah I Deshmukh CT. Intramuscular midazolam vs intravenous diazepam for acute seizures. Indian J Pediatr 2005; 72: 667–670.
Crossref
Google Scholar
44. Ahmad S Ellis JC Kamwendo H Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: An open randomised trial. Lancet 2006; 367: 1591–1597.
Crossref
Google Scholar
45. Bhattacharyya M Kalra V Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol 2006; 34: 355–359.
Crossref
ISI
Google Scholar
46. Mittal P Manohar R Rawat AK. Comparative study of intranasal midazolam and intravenous diazepam sedation for procedures and seizures. Indian J Pediatr 2006; 73: 975–978.
Crossref
Google Scholar
47. Mpimbaza A Ndeezi G Staedke S Rosenthal PJ Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: A randomized clinical trial. Pediatrics 2008; 121: e58–64. doi:10.1542/peds.2007-0930.
Crossref
ISI
Google Scholar
48. Talukdar B Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: A randomized controlled trial. Brain Dev 2009; 31: 744–749.
Crossref
ISI
Google Scholar
49. Sreenath TG Gupta P Sharma KK Krishnamurthy S. Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial. Eur J Paediatr Neurol 2010; 14: 162–168.
Crossref
Google Scholar
50. Ashrafi MR Khosroshahi N Karimi P Malamiri RA Bavarian B Zarch AV Mirzaei M Kompani F. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. Eur J Paediatr Neurol 2010; 14: 434–438.
Crossref
Google Scholar
51. Holsti M Dudley N Schunk J Adelgais K Greenberg R Olsen C Healy A Firth S Filloux F. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med 2010; 164: 747–753.
Crossref
Google Scholar
52. Arya R Gulati S Kabra M Sahu JK Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: A randomized open-label study. Epilepsia 2011; 52: 788–793.
Crossref
ISI
Google Scholar
53. Javadzadeh M Sheibani K Hashemieh M Saneifard H. Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: A randomized clinical trial. Iranian J Pediatr 2012; 22: 1–8.
Google Scholar
54. Malu CK Kahamba DM Walker TD Mukampunga C Musalu EM Kokolomani J Mayamba RM Wilmshurst JM Dubru JM Misson JP. Efficacy of sublingual lorazepam versus intrarectal diazepam for prolonged convulsions in Sub-Saharan Africa. J Child Neurol 2013; 29: 895–902.
Crossref
Google Scholar
55. Portela JL Garcia PC Piva JP Barcelos A Bruno F Branco R Tasker RC. Intramuscular midazolam versus intravenous diazepam for treatment of seizures in the pediatric emergency department: A randomized clinical trial. Med Intensiva 2014; 39: 160–166.
Crossref
Google Scholar
56. Rai A Aggarwal A Mittal H Sharma S. Comparative efficacy and safety of intravenous valproate and phenytoin in children. Pediatr Neurol 2011; 45: 300–304.
Crossref
Google Scholar
57. Welch RD Nicholas K Durkalski-Mauldin VL Lowenstein DH Conwit R Mahajan PV Lewandowski C Silbergleit R; Neurological Emergencies Treatment Trials (NETT) Network Investigators. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia 2015; 56: 254–262.
Crossref
Google Scholar
58. Malamiri RA Ghaempanah M Khosroshahi N Nikkhah A Bavarian B Ashrafi MR. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: A randomised trial. Eur J Paediatr Neurol 2012; 16: 536–541.
Crossref
Google Scholar
59. Cereghino JJ Mitchell WG Murphy J Kriel RL Rosenfeld WE Trevathan E. Treating repetitive seizures with a rectal diazepam formulation: A randomized study. The North American Diastat Study Group. Neurology 1998; 51: 1274–1282.
Crossref
ISI
Google Scholar
60. Dreifuss FE Rosman NP Cloyd JC Pellock JM Kuzniecky RI Lo WD Matsuo F Sharp GB Conry JA Bergen DC Bell WE. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998; 338: 1869–1875.
Crossref
ISI
Google Scholar
61. Cloyd J. Pharmacologic considerations in the treatment of repetitive or prolonged seizures. J Child Neurol 2007; 22(suppl 5): 47S–52S.
Crossref
Google Scholar
62. McMullan J Sasson C Pancioli A Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: A meta-analysis. Acad Emerg Med 2010; 17: 575–582.
Crossref
ISI
Google Scholar
63. DeToledo JC Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: Improved tolerability versus increased costs. Drug Saf 2000; 22: 459–466.
Crossref
Google Scholar
64. Bleck T Cock H Chamberlain J Cloyd J Connor J Elm J Fountain N Jones E Lowenstein D Shinnar S Silbergleit R Treiman D Trinka E Kapur J. The established status epilepticus trial 2013. Epilepsia 2013; 54(suppl 6): 89–92.
Crossref
Google Scholar
65. Brophy GM Bell R Claassen J Alldredge B Bleck TP Glauser T Laroche SM Riviello JJ Jr, Shutter L Sperling MR Treiman DM Vespa PM; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17: 3–23.
Crossref
ISI
Google Scholar
66. Mehta V Singhi P Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: A randomized controlled trial. J Child Neurol 2007; 22: 1191–1197.
Crossref
ISI
Google Scholar
67. Abend NS Monk HM Licht DJ Dlugos DJ. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. Pediatr Crit Care Med 2009; 10: 505–510.
Crossref
ISI
Google Scholar
68. Aiguabella M Falip M Villanueva V de la Peña P Molins A Garcia-Morales I Saiz RA Pardo J Tortosa D Sansa G Miró J. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: A multicentric observational study. Seizure 2011; 20: 60–64.
Crossref
Google Scholar
69. Alvarez V Januel JM Burnand B Rossetti AO. Second-line status epilepticus treatment: Comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011; 52: 1292–1296.
Crossref
Google Scholar
70. Goraya JS Khurana DS Valencia I Melvin JJ Cruz M Legido A Kothare SV. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008; 38: 177–180.
Crossref
ISI
Google Scholar
71. Ruegg S Hunziker P Marsch S Schindler C. Association of environmental factors with the onset of status epilepticus. Epilepsy Behav 2008; 12: 66–73.
Crossref
Google Scholar
72. Santamarina E Toledo M Sueiras M Raspall M Ailouti N Lainez E Porta I De Gracia R Quintana M Alvarez-Sabín J Salas-Puig J. Usefulness of intravenous lacosamide in status epilepticus. J Neurol 2013; 260: 3122–3128.
Crossref
ISI
Google Scholar

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
EMAIL ARTICLE LINK
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the Sage Journals article sharing page.

Information, rights and permissions

Information

Published In

Volume 16, Issue 1
Pages: 48 - 61
Article first published online: January 1, 2016
Issue published: January - February 2016

Rights and permissions

© 2016 SAGE Publications.
Request permissions for this article.
PubMed: 26900382

Authors

Affiliations

Tracy Glauser, MD
Division of Neurology, Comprehensive Epilepsy Center, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH
[email protected]
View all articles by this author
Shlomo Shinnar, MD, PhD
Departments of Neurology, Pediatrics, and Epidemiology and Population Health, and the Comprehensive Epilepsy Management Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
View all articles by this author
David Gloss, MD
CAMC Neurology Group, Charleston, WV
View all articles by this author
Brian Alldredge, PharmD
School of Pharmacy, University of California, San Francisco, CA
View all articles by this author
Ravindra Arya, MD, DM
Division of Neurology, Comprehensive Epilepsy Center, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH
View all articles by this author
Jacquelyn Bainbridge, PharmD
Department of Clinical Pharmacy, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO
View all articles by this author
Mary Bare, MSPH, RN
Division of Neurology, Comprehensive Epilepsy Center, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH
View all articles by this author
Thomas Bleck, MD
Departments of Neurological Sciences, Neurosurgery, Medicine, and Anesthesiology, Rush University Medical Center, Chicago, IL
View all articles by this author
W. Edwin Dodson, MD
Departments of Neurology and Pediatrics, Washington University School of Medicine, St. Louis, MO
View all articles by this author
Lisa Garrity, PharmD
Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
View all articles by this author
Andy Jagoda, MD
Department of Emergency Medicine, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, NY
View all articles by this author
Daniel Lowenstein, MD
Department of Neurology, University of California, San Francisco, CA
View all articles by this author
John Pellock, MD
Division of Pediatric Neurology, Virginia Commonwealth University, Richmond, VA
View all articles by this author
James Riviello, MD
NYU Comprehensive Epilepsy Center, New York, NY
View all articles by this author
Edward Sloan, MD, MPH
Department of Emergency Medicine, University of Illinois at Chicago, Chicago, IL
View all articles by this author
David M. Treiman, MD
Division of Neurology, Barrow Neurological Institute, Phoenix, AZ
View all articles by this author

Notes

Address correspondence to Tracy Glauser, MD, Cincinnati Children's Hospital Medical Center, Division of Neurology, MLC 2015, 3333 Burnet Ave., Cincinnati, OH 45229-3026. E-mail: [email protected]
The following organizations have endorsed this guideline: Epilepsy Foundation, Child Neurology Society, American College of Emergency Physicians, Association of Child Neurology Nurses, American Association of Neuroscience Nurses

Metrics and citations

Metrics

Journals metrics

This article was published in Epilepsy Currents.

VIEW ALL JOURNAL METRICS

Article usage*

Total views and downloads: 112572

*Article usage tracking started in December 2016

Altmetric

See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores


Articles citing this one

Receive email alerts when this article is cited

Web of Science: 694 view articles Opens in new tab

Crossref: 809

  1. Sustained effort network for treatment of status epilepticus/European ...
    Go to citation Crossref Google Scholar
  2. Best practices for the management of febrile seizures in children
    Go to citation Crossref Google Scholar
  3. Use of perampanel oral suspension for the treatment of refractory and ...
    Go to citation Crossref Google Scholar
  4. Investigating Associations Between Nonadherence to Guideline-Recommend...
    Go to citation Crossref Google Scholar
  5. A retrospective study of CT scan utilization in the emergency departme...
    Go to citation Crossref Google Scholar
  6. Survey of Pediatric Status Epilepticus Treatment Practices and Adheren...
    Go to citation Crossref Google Scholar
  7. Outcome of emergency neurosurgery in patients with refractory and supe...
    Go to citation Crossref Google Scholar
  8. Relative Bioavailability Study of Midazolam Intramuscularly Administer...
    Go to citation Crossref Google Scholar
  9. Update in Pediatric Neurocritical Care: What a Neurologist Caring for ...
    Go to citation Crossref Google Scholar
  10. The influence of biological rhythms on the initial onset of status epi...
    Go to citation Crossref Google Scholar
  11. Management of Pediatric Convulsive Status Epilepticus From the Perspec...
    Go to citation Crossref Google Scholar
  12. Adapting evidence-based practice guidelines for emergency management o...
    Go to citation Crossref Google Scholar
  13. Enteral Ketamine for Status Epilepticus in Children with Epilepsy
    Go to citation Crossref Google Scholar
  14. Excessive Use of Benzodiazepines Is a Risk Factor for Endotracheal Int...
    Go to citation Crossref Google Scholar
  15. Time-sensitive healthcare guidelines for youth with chronic diseases i...
    Go to citation Crossref Google Scholar
  16. Electroconvulsive therapy in new onset refractory status epilepticus (...
    Go to citation Crossref Google Scholar
  17. The lactate receptor HCAR1: A key modulator of epileptic seizure activ...
    Go to citation Crossref Google Scholar
  18. Status epilepticus: modern views on classification, typology, methods ...
    Go to citation Crossref Google Scholar
  19. Status epilepticus in Auckland, New Zealand: Treatment patterns and de...
    Go to citation Crossref Google Scholar
  20. Status Epilepticus: An Update on Pharmacological Management
    Go to citation Crossref Google Scholar
  21. The Evolving Role of Electroencephalography in Postarrest Care
    Go to citation Crossref Google Scholar
  22. An Emergency Department Quality Improvement Project for Intravenous Le...
    Go to citation Crossref Google ScholarPub Med
  23. Delayed Deterioration of Electroencephalogram in Patients with Cardiac...
    Go to citation Crossref Google Scholar
  24. Standardizing the Treatment for Pediatric Status Epilepticus: A Qualit...
    Go to citation Crossref Google Scholar
  25. Drug therapy problems and contributing factors among patients with epi...
    Go to citation Crossref Google Scholar
  26. Reducing Time to Electroencephalography in Pediatric Convulsive Status...
    Go to citation Crossref Google Scholar
  27. Ketamine Efficacy for Management of Status Epilepticus: Considerations...
    Go to citation Crossref Google Scholar
  28. Efficacy of a combined anti-seizure treatment against cholinergic esta...
    Go to citation Crossref Google Scholar
  29. Rapid administration of undiluted loading doses of levetiracetam
    Go to citation Crossref Google Scholar
  30. General Anesthesia Exposure in Infancy and Childhood: A 10-year Biblio...
    Go to citation Crossref Google Scholar
  31. Try, Try Again: Success Rates After Continued Treatment Attempts in Re...
    Go to citation Crossref Google Scholar
  32. Evaluation of Goal Phenytoin Levels After an Initial Intravenous Loadi...
    Go to citation Crossref Google ScholarPub Med
  33. Rapid Rescue Treatment with Diazepam Nasal Spray Leads to Faster Seizu...
    Go to citation Crossref Google Scholar
  34. Evaluation of Midazolam-Ketamine-Allopregnanolone Combination Therapy ...
    Go to citation Crossref Google Scholar
  35. Evidence Implicating Blood-Brain Barrier Impairment in the Pathogenesi...
    Go to citation Crossref Google Scholar
  36. Stati di male epilettico: diagnosi e trattamento
    Go to citation Crossref Google Scholar
  37. Post Cardiac Arrest Care in the Cardiac Intensive Care Unit
    Go to citation Crossref Google Scholar
  38. The Role of Early Intubation in Status Epilepticus with Out-of-Hospita...
    Go to citation Crossref Google Scholar
  39. Status epilepticus in BRAF‐related cardio‐facio‐cutaneous syndrome: Fo...
    Go to citation Crossref Google Scholar
  40. Staged treatment response in status epilepticus: Lessons from the ...
    Go to citation Crossref Google Scholar
  41. A proposal for a shared therapeutic algorithm in children with prolong...
    Go to citation Crossref Google Scholar
  42. How Intuitive Is the Administration of Pediatric Emergency Medication ...
    Go to citation Crossref Google Scholar
  43. Application of ensemble learning for predicting GABAA receptor agonist...
    Go to citation Crossref Google Scholar
  44. 2023 American Heart Association Focused Update on Adult Advanced Cardi...
    Go to citation Crossref Google Scholar
  45. Efficacy of intravenous clonazepam for paediatric convulsive status ep...
    Go to citation Crossref Google Scholar
  46. Association Between Dose Escalation of Anesthetics and Outcomes in Pat...
    Go to citation Crossref Google Scholar
  47. Correlation between Persistent Serum Lactate Elevation and Brain Magne...
    Go to citation Crossref Google Scholar
  48. Questions and Controversies in Neonatal Seizures
    Go to citation Crossref Google Scholar
  49. Epilepsy monitoring unit practices and safety among NAEC epilepsy cent...
    Go to citation Crossref Google Scholar
  50. A patient-centered equilibrium strategy for selecting anti-epileptic d...
    Go to citation Crossref Google Scholar
  51. ACVIM Consensus Statement on the management of status ep...
    Go to citation Crossref Google Scholar
  52. Status epilepticus in the ICU
    Go to citation Crossref Google Scholar
  53. Notfalltherapie
    Go to citation Crossref Google Scholar
  54. Pharmacology of Psychiatric and Neurologic Drugs
    Go to citation Crossref Google Scholar
  55. Seizure: Prophylaxis and Treatment in Acute Brain Injury
    Go to citation Crossref Google Scholar
  56. Management strategies for refractory status epilepticus
    Go to citation Crossref Google Scholar
  57. A Fatal Case of Opioid Body Packer Syndrome Presented with Seizures
    Go to citation Crossref Google Scholar
  58. PICU Admission of Children for Status Epilepticus: Is There a Differen...
    Go to citation Crossref Google Scholar
  59. How much refractory is ‘refractory status epilepticus’? A retrospectiv...
    Go to citation Crossref Google Scholar
  60. Development and validation of a nomogram to provide individualized pre...
    Go to citation Crossref Google Scholar
  61. Sex-related differences in adult patients with status epilepticus: a s...
    Go to citation Crossref Google Scholar
  62. Comparing effects and application of telemedicine for different specia...
    Go to citation Crossref Google Scholar
  63. Review of Noninvasive Neuromonitoring Modalities in Children II: EEG, ...
    Go to citation Crossref Google Scholar
  64. Ensuring Emergency Readiness in the Pediatric Primary Care Setting: An...
    Go to citation Crossref Google Scholar
  65. Seizure recurrences in generalized convulsive status epilepticus under...
    Go to citation Crossref Google Scholar
  66. Risk assessment of long-term epilepsy after de novo status epilepticus...
    Go to citation Crossref Google Scholar
  67. Increased Susceptibility to Pilocarpine-Induced Status Epilepticus and...
    Go to citation Crossref Google Scholar
  68. Automated diagnosis of EEG abnormalities with different classification...
    Go to citation Crossref Google Scholar
  69. Neurologic Complications of Cancer Immunotherapy
    Go to citation Crossref Google Scholar
  70. Factors influencing the success and complications of intraosseous acce...
    Go to citation Crossref Google Scholar
  71. Neuroinflammation and status epilepticus: a narrative review unravelin...
    Go to citation Crossref Google Scholar
  72. Adverse events of undiluted intravenous push levetiracetam
    Go to citation Crossref Google Scholar
  73. The initial treatment in convulsive status epilepticus in China: A mul...
    Go to citation Crossref Google Scholar
  74. Analysis of Adverse Drug Reactions in Pediatric Patients with Epilepsy...
    Go to citation Crossref Google Scholar
  75. Status epilepticus in adults: a clinically oriented review of etiologi...
    Go to citation Crossref Google Scholar
  76. Trends and Differences in Status Epilepticus Treatment of Children and...
    Go to citation Crossref Google Scholar
  77. The real-world effectiveness of intravenous brivaracetam as a second-l...
    Go to citation Crossref Google Scholar
  78. The Clinical Efficacy and Safety of Acute Care Setting for Intravenous...
    Go to citation Crossref Google Scholar
  79. Ketamine to Prevent Endotracheal Intubation in Adults with Refractory ...
    Go to citation Crossref Google Scholar
  80. Advances in the Treatment of Status Epilepticus
    Go to citation Crossref Google Scholar
  81. A Comparison of Ketamine and Midazolam as First-Line Anesthetic Infusi...
    Go to citation Crossref Google Scholar
  82. Indications for the use of intravenous second-line antiseizure medicat...
    Go to citation Crossref Google Scholar
  83. Safety and Tolerability of Intravenous Push Lacosamide and Levetiracet...
    Go to citation Crossref Google ScholarPub Med
  84. Suboptimal Dosing of Benzodiazepines and Levetiracetam in a Cohort of ...
    Go to citation Crossref Google ScholarPub Med
  85. Treatment Guideline Nonadherence Pretransport Associated With Need for...
    Go to citation Crossref Google Scholar
  86. Nonconvulsive Status Epilepticus: A Review for Emergency Clinicians
    Go to citation Crossref Google Scholar
  87. Febrile Seizures
    Go to citation Crossref Google Scholar
  88. Real-life evidence about the use of intravenous brivaracetam in urgent...
    Go to citation Crossref Google Scholar
  89. Comparison of the status epilepticus severity score and the epidemiolo...
    Go to citation Crossref Google Scholar
  90. Early and established status epilepticus: The impact of timing of inte...
    Go to citation Crossref Google Scholar
  91. Relevamiento de recursos disponibles para el manejo de status epilépti...
    Go to citation Crossref Google Scholar
  92. Long-term follow-up of phenobarbital versus valproate for generalized ...
    Go to citation Crossref Google Scholar
  93. Prediction of long‐term unprovoked seizures after status epilepticus
    Go to citation Crossref Google Scholar
  94. Letter to the editor regarding “early timing of anesthesia in status e...
    Go to citation Crossref Google Scholar
  95. Duration of constant rate infusion with diazepam or propofol for canin...
    Go to citation Crossref Google Scholar
  96. A Practical Approach to Super Refractory Status Epilepticus in Pediatr...
    Go to citation Crossref Google Scholar
  97. Prognostic indicators of non-convulsive status epilepticus in intensiv...
    Go to citation Crossref Google Scholar
  98. Management of status epilepticus in Malaysia: A national survey of cur...
    Go to citation Crossref Google Scholar
  99. Acute Abortive Therapies for Seizure Clusters in Long-Term Care
    Go to citation Crossref Google Scholar
  100. Factors Associated With Improved Pediatric Resuscitative Care in Gener...
    Go to citation Crossref Google Scholar
  101. Electrographic seizure duration and inter‐seizure intervals in focal s...
    Go to citation Crossref Google Scholar
  102. Early Clinical Variables Associated With Refractory Convulsive Status ...
    Go to citation Crossref Google Scholar
  103. Sublingual lorazepam as rescue therapy for seizure emergencies in adul...
    Go to citation Crossref Google Scholar
  104. Post-stroke epileptic seizures: risk factors, clinical presentation, p...
    Go to citation Crossref Google Scholar
  105. Pediatric Status Epilepticus: Treat Early and Avoid Delays
    Go to citation Crossref Google Scholar
  106. Status Epilepticus
    Go to citation Crossref Google Scholar
  107. Management of children with febrile seizures: a Greek nationwide surve...
    Go to citation Crossref Google Scholar
  108. Status epilepticus prognosis following levetiracetam administration: A...
    Go to citation Crossref Google Scholar
  109. The role of dexmedetomidine in post cranioplasty refractory status epi...
    Go to citation Crossref Google Scholar
  110. Adult epilepsy
    Go to citation Crossref Google Scholar
  111. Self-management education for children with epilepsy and their caregiv...
    Go to citation Crossref Google Scholar
  112. Treatment of pediatric convulsive status epilepticus
    Go to citation Crossref Google Scholar
  113. Comparison of Safety and Effectiveness between Levetiracetam and Pheny...
    Go to citation Crossref Google Scholar
  114. Epileptic Status in a PEDiatric cohort ( ...
    Go to citation Crossref Google Scholar
  115. Phenobarbital in super‐refractory status epilepticus ( P...
    Go to citation Crossref Google Scholar
  116. Prehospital Seizure Management in Children: An Evaluation of a Nationa...
    Go to citation Crossref Google Scholar
  117. Current evidence and clinical utility of phenobarbital for alcohol wit...
    Go to citation Crossref Google Scholar
  118. Association Between Induced Burst Suppression and Clinical Outcomes in...
    Go to citation Crossref Google Scholar
  119. Overcoming barriers to the management of seizure clusters: ease of use...
    Go to citation Crossref Google Scholar
  120. Epidemiology, real-world treatment and mortality of patients with stat...
    Go to citation Crossref Google Scholar
  121. Black-Box Warnings of Antiseizure Medications: What is Inside the Box?
    Go to citation Crossref Google Scholar
  122. Compliance with status epilepticus management protocol and effect on c...
    Go to citation Crossref Google Scholar
  123. Comparing Patients With Isolated Seizures and Status Epilepticus in In...
    Go to citation Crossref Google Scholar
  124. Early identification of NORSE and transfer to care setting with approp...
    Go to citation Crossref Google Scholar
  125. Management of convulsive status epilepticus: recent updates
    Go to citation Crossref Google Scholar
  126. Assessment of First-line Therapy With Midazolam for Prehospital Seizur...
    Go to citation Crossref Google Scholar
  127. Retrospective External Validation of the Status Epilepticus Severity S...
    Go to citation Crossref Google Scholar
  128. Use of Continuous Ketamine Infusion as an Adjunctive Agent in Young In...
    Go to citation Crossref Google Scholar
  129. Ketamine as advanced second‐line treatment in benzodiazepine‐refractor...
    Go to citation Crossref Google Scholar
  130. Preclinical pharmacokinetics and tolerability of a novel meglumine‐bas...
    Go to citation Crossref Google Scholar
  131. The role of neutrophil-to-lymphocyte ratio in predicting outcomes in p...
    Go to citation Crossref Google Scholar
  132. Status epilepticus and benzodiazepine treatment: Use, underdosing and ...
    Go to citation Crossref Google Scholar
  133. Why ketamine
    Go to citation Crossref Google Scholar
  134. Phenobarbital in Status epilepticus – Rediscovery of an effective drug
    Go to citation Crossref Google Scholar
  135. Fifty years of research on status epilepticus: Seizures use hippocampa...
    Go to citation Crossref Google Scholar
  136. Survey of Pediatric ICU EEG Monitoring–Reassessment After a Decade
    Go to citation Crossref Google Scholar
  137. Clinical Features and Management of Status Epilepticus in the Pediatri...
    Go to citation Crossref Google Scholar
  138. The Roles of Glutamate Receptors and Their Antagonists in Status Epile...
    Go to citation Crossref Google Scholar
  139. Treatment of benzodiazepine-refractory status epilepticus: A retrospec...
    Go to citation Crossref Google Scholar
  140. Status Epilepticus in Older Adults: Diagnostic and Treatment Considera...
    Go to citation Crossref Google Scholar
  141. Reducing seizure to needle times in nonconvulsive status epilepticus w...
    Go to citation Crossref Google Scholar
  142. Status Epilepticus in an Internal Medicine Ward: Different Patients Th...
    Go to citation Crossref Google Scholar
  143. Neurotoxicity evoked by organophosphates and available countermeasures
    Go to citation Crossref Google Scholar
  144. The Midazolam RAMPART Study Medical Records Project: A Unique Use of R...
    Go to citation Crossref Google Scholar
  145. Childhood seizures
    Go to citation Crossref Google Scholar
  146. Evaluation and practical management: Approach to simple and complex fe...
    Go to citation Crossref Google Scholar
  147. Pharmacist involvement with antiepileptic therapy for status epileptic...
    Go to citation Crossref Google Scholar
  148. Status Epilepticus
    Go to citation Crossref Google Scholar
  149. Neuropharmacology in the Intensive Care Unit
    Go to citation Crossref Google Scholar
  150. Challenges for Emergency Medical Services in Status Epilepticus Manage...
    Go to citation Crossref Google Scholar
  151. The potential of intravenous topiramate for the treatment of status ep...
    Go to citation Crossref Google Scholar
  152. Progress in the Research of Convulsive Status Epilepticus in Children
    Go to citation Crossref Google Scholar
  153. What Is Known about Midazolam? A Bibliometric Approach of the Literatu...
    Go to citation Crossref Google Scholar
  154. Choice of antiepileptic in benzodiazepines refractory convulsive statu...
    Go to citation Crossref Google Scholar
  155. Comparison of Phenytoin and Fosphenytoin in Treatment of Active Seizur...
    Go to citation Crossref Google Scholar
  156. Acute perioperative neurological emergencies
    Go to citation Crossref Google Scholar
  157. Neurological Emergencies in the Intensive Care Unit
    Go to citation Crossref Google Scholar
  158. Optimizing Status Epilepticus Management in the Emergency Department
    Go to citation Crossref Google Scholar
  159. 20. Neurological Disorders
    Go to citation Crossref Google Scholar
  160. Management of Status Epilepticus by Different Pediatric Departments: N...
    Go to citation Crossref Google Scholar
  161. Does Initiation of Prophylactic Antiseizure Medication Improve Neurolo...
    Go to citation Crossref Google Scholar
  162. Risk factors for super-refractory and mortality in generalized convuls...
    Go to citation Crossref Google Scholar
  163. A Pilot Study of High-Definition Transcranial Direct Current Stimulati...
    Go to citation Crossref Google Scholar
  164. Vascular topology and blood flow are acutely impacted by experimental ...
    Go to citation Crossref Google ScholarPub Med
  165. Tumor Related Epilepsy
    Go to citation Crossref Google Scholar
  166. Incidence of adverse events for procedural sedation and analgesia for ...
    Go to citation Crossref Google Scholar
  167. Neurologic Conditions: Stingers, Headaches, and Seizures
    Go to citation Crossref Google Scholar
  168. Acute seizure therapies in people with epilepsy: Fact or fiction? A U....
    Go to citation Crossref Google Scholar
  169. The Feasibility of a Pediatric Distance Learning Curriculum for Emerge...
    Go to citation Crossref Google Scholar
  170. Status epilepticus in pregnancy
    Go to citation Crossref Google Scholar
  171. Peripartum Status Epilepticus: Twitching with a Twist
    Go to citation Crossref Google Scholar
  172. Pediatric Status Epilepticus Severity Score (STEPSS): Predictive Perfo...
    Go to citation Crossref Google ScholarPub Med
  173. Oral bioavailability of microdoses and therapeutic doses of midazolam ...
    Go to citation Crossref Google Scholar
  174. Development and Validation of a Nomogram Based on the Epidemiology-Bas...
    Go to citation Crossref Google Scholar
  175. Evaluation and Treatment of Adult Status Epilepticus in the Emergency ...
    Go to citation Crossref Google Scholar
  176. Improving time to administration of time-critical medications in the p...
    Go to citation Crossref Google Scholar
  177. In reply
    Go to citation Crossref Google Scholar
  178. The IN-MIDAZ study – Intranasal midazolam in aborting seizures – An ep...
    Go to citation Crossref Google Scholar
  179. Factors associated with mortality in patients with super-refractory st...
    Go to citation Crossref Google Scholar
  180. Prognostic effects of treatment protocols for febrile convulsive statu...
    Go to citation Crossref Google Scholar
  181. Timing matters: there are significant differences in short-term outcom...
    Go to citation Crossref Google Scholar
  182. Early clinical features of new-onset refractory status epilepticus (NO...
    Go to citation Crossref Google Scholar
  183. Treatment of status epilepticus in pediatrics: curriculum learning com...
    Go to citation Crossref Google Scholar
  184. Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status ...
    Go to citation Crossref Google Scholar
  185. Brain tumor related epilepsy: pathophysiological approaches and ration...
    Go to citation Crossref Google Scholar
  186. Two cases of anesthetics-induced epileptic seizures: a case report and...
    Go to citation Crossref Google Scholar
  187. Treatment delay in status epilepticus: Time to launch another “Time is...
    Go to citation Crossref Google Scholar
  188. Predicting the progression to super-refractory status epilepticus: A m...
    Go to citation Crossref Google Scholar
  189. Education Research: High-Fidelity Simulation to Evaluate Diagnostic Re...
    Go to citation Crossref Google Scholar
  190. Constant rate infusion of diazepam or propofol for the management of c...
    Go to citation Crossref Google Scholar
  191. Management and prognosis of pediatric status epilepticus
    Go to citation Crossref Google Scholar
  192. Therapeutically induced EEG burst-suppression pattern to treat refract...
    Go to citation Crossref Google Scholar
  193. Estatus epiléptico focal: revisión del tratamiento farmacológico
    Go to citation Crossref Google Scholar
  194. Hazardous use of benzodiazepine receptor agonists in psychiatric clini...
    Go to citation Crossref Google Scholar
  195. International consensus recommendations for management of new onset re...
    Go to citation Crossref Google Scholar
  196. Focal status epilepticus: a review of pharmacological treatment
    Go to citation Crossref Google Scholar
  197. Fosphenytoin dosing regimen including optimal timing for the measureme...
    Go to citation Crossref Google Scholar
  198. Treatment of benzodiazepine-resistant status epilepticus: Systematic r...
    Go to citation Crossref Google Scholar
  199. Quality of critical care clinical practice guidelines involving pharma...
    Go to citation Crossref Google Scholar
  200. Implementation of neurocritical care in Thailand
    Go to citation Crossref Google Scholar
  201. Refractory Status Epilepticus
    Go to citation Crossref Google Scholar
  202. Real-World Midazolam Use and Outcomes With Out-of-Hospital Treatment o...
    Go to citation Crossref Google Scholar
  203. Current Management of Generalized Convulsive Status Epilepticus in Chi...
    Go to citation Crossref Google Scholar
  204. Out‐of‐hospital versus in‐hospital status epilepticus: The role of eti...
    Go to citation Crossref Google Scholar
  205. Status Epilepticus Australasian Registry for Children: A pilot prospec...
    Go to citation Crossref Google Scholar
  206. Ketamine for Management of Neonatal and Pediatric Refractory Status Ep...
    Go to citation Crossref Google Scholar
  207. The Frequency of Refractory Status Epilepticus and Its Outcome in a Te...
    Go to citation Crossref Google Scholar
  208. Benzodiazepines in the Management of Seizures and Status Epilepticus: ...
    Go to citation Crossref Google Scholar
  209. Pharmacist involvement with antiepileptic therapy for status epileptic...
    Go to citation Crossref Google Scholar
  210. Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosp...
    Go to citation Crossref Google Scholar
  211. Nanocarrier facilitated drug delivery to the brain through intranasal ...
    Go to citation Crossref Google Scholar
  212. Manejo y factores de riesgo de mortalidad del estatus epiléptico: estu...
    Go to citation Crossref Google Scholar
  213. Status epilepticus management and mortality risk factors: a retrospect...
    Go to citation Crossref Google Scholar
  214. Evaluation of phenytoin loading doses in overweight patients using act...
    Go to citation Crossref Google Scholar
  215. Valproate in status epilepticus: Correlation between loading dose, ser...
    Go to citation Crossref Google Scholar
  216. Intravenous ganaxolone for the treatment of refractory status epilepti...
    Go to citation Crossref Google Scholar
  217. The Utilization of Critical Care Resources in Pediatric Neurocritical ...
    Go to citation Crossref Google Scholar
  218. Reponse of second-line treatment in focal status epilepticus: A tertia...
    Go to citation Crossref Google Scholar
  219. Benzodiazepine Use for Pediatric Patients With Suspected Nonconvulsive...
    Go to citation Crossref Google Scholar
  220. Seizures in the Radiology Department
    Go to citation Crossref Google Scholar
  221. Publications in Pediatric Epilepsy: Using Bibliometrics to Determine R...
    Go to citation Crossref Google ScholarPub Med
  222. High risk and low prevalence diseases: Eclampsia
    Go to citation Crossref Google Scholar
  223. Prehospital benzodiazepine use and need for respiratory support in pae...
    Go to citation Crossref Google Scholar
  224. Conocimiento de los residentes de especialidades médico-quirúrgicas en...
    Go to citation Crossref Google Scholar
  225. Updated review of rescue treatments for seizure clusters and prolonged...
    Go to citation Crossref Google Scholar
  226. Efficacy of intravenous levetiracetam versus phenytoin in convulsive s...
    Go to citation Crossref Google Scholar
  227. Management of the first stage of convulsive status epilepticus in adul...
    Go to citation Crossref Google Scholar
  228. Molecular Mechanisms of Epilepsy: The Role of the Chloride Transporter...
    Go to citation Crossref Google Scholar
  229. Encéphalite en réanimation
    Go to citation Crossref Google Scholar
  230. Why won’t it stop? The dynamics of benzodiazepine resistance in status...
    Go to citation Crossref Google Scholar
  231. Lack of clinically relevant differences in safety and pharmacokinetics...
    Go to citation Crossref Google Scholar
  232. Status Epilepticus and EEG Monitoring
    Go to citation Crossref Google Scholar
  233. Parenteral Long-Acting Antiseizure Medications Are Used More Often to ...
    Go to citation Crossref Google ScholarPub Med
  234. Quantitative EEG-Based Seizure Estimation in Super-Refractory Status E...
    Go to citation Crossref Google Scholar
  235. Bioavailability and Safety of a New Highly Concentrated Midazolam Nasa...
    Go to citation Crossref Google Scholar
  236. PICU Pharmacology
    Go to citation Crossref Google Scholar
  237. Simulation-based assessment of trainee’s performance in post-cardiac a...
    Go to citation Crossref Google Scholar
  238. Profiles of indigenous patients with epilepsy in a Brazilian village
    Go to citation Crossref Google Scholar
  239. Ketamine in adult super‐refractory status epilepticus: Efficacy analys...
    Go to citation Crossref Google Scholar
  240. The safety of rapid infusion levetiracetam: A systematic review
    Go to citation Crossref Google Scholar
  241. Beta-caryophyllene attenuates short-term recurrent seizure activity an...
    Go to citation Crossref Google Scholar
  242. Cattle Bile Arisaema Aqueous Extracts Protect Against Febrile Seizures...
    Go to citation Crossref Google Scholar
  243. The Effectiveness of Intranasal Midazolam for the Treatment of Prehosp...
    Go to citation Crossref Google Scholar
  244. Time Elapsed from Onset of Pediatric Convulsive Status Epilepticus to ...
    Go to citation Crossref Google Scholar
  245. Evaluation of changes in physician behavior after introduction of pedi...
    Go to citation Crossref Google Scholar
  246. The effectiveness of intravenous benzodiazepine for status epilepticus...
    Go to citation Crossref Google Scholar
  247. La relevancia del tiempo en la epilepsia parcial continua
    Go to citation Crossref Google Scholar
  248. The importance of timing in epilepsia partialis continua
    Go to citation Crossref Google Scholar
  249. Defining and overcoming the therapeutic obstacles in canine refractory...
    Go to citation Crossref Google Scholar
  250. New‐onset non‐lesional aphasic status epilepticus. Clinical descriptio...
    Go to citation Crossref Google Scholar
  251. Status epilepticus: review on diagnosis, monitoring and treatment
    Go to citation Crossref Google Scholar
  252. Leveraging EHR Data to Evaluate the Association of Late Recognition of...
    Go to citation Crossref Google Scholar
  253. Nervous System Emergencies
    Go to citation Crossref Google Scholar
  254. Modern Treatment of Status Epilepticus in Adults
    Go to citation Crossref Google Scholar
  255. Status epilepticus in pregnancy: a literature review and a protocol pr...
    Go to citation Crossref Google Scholar
  256. PERMIT study: a global pooled analysis study of the effectiveness and ...
    Go to citation Crossref Google Scholar
  257. Factors associated with the use of anesthetic drug infusion in patient...
    Go to citation Crossref Google Scholar
  258. The emergency neurology literature 2020
    Go to citation Crossref Google Scholar
  259. Recurrent status epilepticus: Clinical features and recurrence risk in...
    Go to citation Crossref Google Scholar
  260. Effectiveness and utility of an electronic intervention for appropriat...
    Go to citation Crossref Google Scholar
  261. Management of Status Epilepticus, Refractory Status Epilepticus, and S...
    Go to citation Crossref Google Scholar
  262. Improving self-efficacy in seizure first aid: Developing a seizure fir...
    Go to citation Crossref Google Scholar
  263. Identifying Barriers to Care in the Pediatric Acute Seizure Care Pathw...
    Go to citation Crossref Google Scholar
  264. Clinical considerations for rapid administration of undiluted or minim...
    Go to citation Crossref Google Scholar
  265. Epidemiology, management and outcome of status epilepticus in adults: ...
    Go to citation Crossref Google Scholar
  266. Specific characteristics and current diagnostic and treatment modaliti...
    Go to citation Crossref Google Scholar
  267. Status epilepticus following vaccination in children aged ≤24 months: ...
    Go to citation Crossref Google Scholar
  268. Pre-hospital and emergency department treatment of convulsive status e...
    Go to citation Crossref Google Scholar
  269. Treating Rhythmic and Periodic EEG Patterns in Comatose Survivors of C...
    Go to citation Crossref Google Scholar
  270. Status Epilepticus: an Overview for Neuroscientists
    Go to citation Crossref Google Scholar
  271. Minimum standards for inpatient long-term video-EEG monitoring: A clin...
    Go to citation Crossref Google Scholar
  272. Management of Status Epilepticus and Indications for Inpatient Electro...
    Go to citation Crossref Google Scholar
  273. Intravenous and Intramuscular Allopregnanolone for Early Treatment of ...
    Go to citation Crossref Google Scholar
  274. Minimum standards for inpatient long‐term video‐electroencephalographi...
    Go to citation Crossref Google Scholar
  275. Status Epilepticus as a Life-Threatening Manifestation of Myxedema Cri...
    Go to citation Crossref Google Scholar
  276. Gabaergic Interneurons in Early Brain Development: Conducting and Orch...
    Go to citation Crossref Google Scholar
  277. A critical review of fosphenytoin sodium injection for the treatment o...
    Go to citation Crossref Google Scholar
  278. Chinese guideline on the application of anti-seizure medications in th...
    Go to citation Crossref Google ScholarPub Med
  279. Anti-convulsant Agents: Phenytoin and Fosphenytoin
    Go to citation Crossref Google Scholar
  280. Guidelines on Anti-convulsant Agents
    Go to citation Crossref Google Scholar
  281. Anti-convulsive Drug Use in Status Therapy: Adults
    Go to citation Crossref Google Scholar
  282. Anti-convulsive Drug Use in Status Treatment in Children
    Go to citation Crossref Google Scholar
  283. Anti-convulsant Agents: Pharmacology and Biochemistry
    Go to citation Crossref Google Scholar
  284. Status Epilepticus
    Go to citation Crossref Google Scholar
  285. Status Epilepticus
    Go to citation Crossref Google Scholar
  286. Barbiturates (Pentobarbital)
    Go to citation Crossref Google Scholar
  287. Status Epilepticus
    Go to citation Crossref Google Scholar
  288. Pediatric Epilepsy Treatment
    Go to citation Crossref Google Scholar
  289. Notfälle der Symptomkontrolle
    Go to citation Crossref Google Scholar
  290. Safety of Intravenous Push Levetiracetam Compared to Intravenous Piggy...
    Go to citation Crossref Google Scholar
  291. Status epilepticus bei Erwachsenen
    Go to citation Crossref Google Scholar
  292. Choice of sedation in neurointensive care
    Go to citation Crossref Google Scholar
  293. Anesthetics for status epilepticus
    Go to citation Crossref Google Scholar
  294. The Critically Ill Child
    Go to citation Crossref Google Scholar
  295. Neurological Emergencies
    Go to citation Crossref Google Scholar
  296. Optimized Benzodiazepine Treatment of Pediatric Status Epilepticus Thr...
    Go to citation Crossref Google Scholar
  297. Status epilepticus outcomes among vaccinated and unvaccinated children...
    Go to citation Crossref Google Scholar
  298. Current and emerging pharmacological treatment for status epilepticus ...
    Go to citation Crossref Google Scholar
  299. Chapter 28: Seizure Disorders
    Go to citation Crossref Google Scholar
  300. Epidemiology and Risk Factors of Convulsive Status Epilepticus Patient...
    Go to citation Crossref Google Scholar
  301. Optimal Management of Status Epilepticus in Children in the Emergency ...
    Go to citation Crossref Google Scholar
  302. First-Response ABCDE Management of Status Epilepticus: A Prospective H...
    Go to citation Crossref Google Scholar
  303. Status Epilepticus in Pediatric Patients in Saudi Arabia: A Systematic...
    Go to citation Crossref Google Scholar
  304. Phenytoin versus other antiepileptic drugs as treatments for status ep...
    Go to citation Crossref Google Scholar
  305. Management of status epilepticus: a narrative review
    Go to citation Crossref Google Scholar
  306. Global transgenic upregulation of KCC2 confers enhanced diazepam effic...
    Go to citation Crossref Google Scholar
  307. Levetiracetam compared with phenytoin or fosphenytoin in benzodiazepin...
    Go to citation Crossref Google Scholar
  308. Epileptic status: reality 2021
    Go to citation Crossref Google Scholar
  309. Isoflurane in (Super-) Refractory Status Epilepticus: A Multicenter Ev...
    Go to citation Crossref Google Scholar
  310. Determinants of nutritional status and outcome in adults with RCSE: a ...
    Go to citation Crossref Google Scholar
  311. First-line management of canine status epilepticus at home and in hosp...
    Go to citation Crossref Google Scholar
  312. Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Eme...
    Go to citation Crossref Google Scholar
  313. Using electronic health data to explore effectiveness of ICU EEG and a...
    Go to citation Crossref Google Scholar
  314. Prolonged mechanical ventilation in patients with terminated status ep...
    Go to citation Crossref Google Scholar
  315. Guidelines for the management of status epilepticus
    Go to citation Crossref Google Scholar
  316. Prehospital Treatment of Status Epilepticus in the United States
    Go to citation Crossref Google Scholar
  317. Management of status epilepticus in patients with liver or kidney dise...
    Go to citation Crossref Google Scholar
  318. Only a Fine Line Separates Genius, Insanity, and Anesthetic Medication...
    Go to citation Crossref Google ScholarPub Med
  319. Treatment of Super-Refractory Status Epilepticus: A Review
    Go to citation Crossref Google ScholarPub Med
  320. Managing Acute Seizures: New Rescue Delivery Option and Resources to A...
    Go to citation Crossref Google ScholarPub Med
  321. Seizure Management in the Intensive Care Unit
    Go to citation Crossref Google Scholar
  322. Phenobarbital versus valproate for generalized convulsive status epile...
    Go to citation Crossref Google Scholar
  323. Benzodiazepine administration patterns before escalation to second‐lin...
    Go to citation Crossref Google Scholar
  324. Status epilepticus suspected autoimmune: Neuronal surface antibodies a...
    Go to citation Crossref Google Scholar
  325. Treating Status Epilepticus: Phenytoin Versus Levetiracetam
    Go to citation Crossref Google Scholar
  326. Persistent Underdosing of Benzodiazepines for Status Epilepticus: The ...
    Go to citation Crossref Google ScholarPub Med
  327. S2k-Leitlinie: Status Epilepticus im Erwachsenenalter
    Go to citation Crossref Google Scholar
  328. Rescue therapies for seizure emergencies: current and future landscape
    Go to citation Crossref Google Scholar
  329. Development of Neurological Emergency Simulations for Assessment: Cont...
    Go to citation Crossref Google Scholar
  330. Diagnosis and Management of Status Epilepticus
    Go to citation Crossref Google Scholar
  331. Nose to Brain Delivery of Phenytoin Sodium Loaded Nano Lipid Carriers:...
    Go to citation Crossref Google Scholar
  332. Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in ...
    Go to citation Crossref Google Scholar
  333. Improving time for administration of second‐line antiseizure medicatio...
    Go to citation Crossref Google Scholar
  334. External evaluation of the predictive performance of seven population ...
    Go to citation Crossref Google Scholar
  335. The Efficacy and Use of a Pocket Card Algorithm in Status Epilepticus ...
    Go to citation Crossref Google Scholar
  336. Practical Considerations for Ketogenic Diet in Adults With Super-Refra...
    Go to citation Crossref Google Scholar
  337. Efficacy and safety of levetiracetam versus (fos)phenytoin for second-...
    Go to citation Crossref Google Scholar
  338. Refractory and Super-Refractory Status Epilepticus in Nerve Agent-Pois...
    Go to citation Crossref Google Scholar
  339. Diagnostic yield of cerebrospinal fluid analysis in status epilepticus...
    Go to citation Crossref Google Scholar
  340. The Pharmacology and Clinical Efficacy of Antiseizure Medications: Fro...
    Go to citation Crossref Google Scholar
  341. Nose-to-brain delivery of phenytoin and its hydrophilic prodrug fosphe...
    Go to citation Crossref Google Scholar
  342. Development and Implementation of a Pediatric Telesimulation Intervent...
    Go to citation Crossref Google Scholar
  343. Clinical phenotypes within nonconvulsive status epilepticus
    Go to citation Crossref Google Scholar
  344. Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatme...
    Go to citation Crossref Google Scholar
  345. Consistent safety and tolerability of Valtoco ® ...
    Go to citation Crossref Google Scholar
  346. Neuropharmacology of Antiseizure Drugs
    Go to citation Crossref Google Scholar
  347. Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine:...
    Go to citation Crossref Google Scholar
  348. Safety and Efficacy of Coma Induction Following First-Line Treatment i...
    Go to citation Crossref Google Scholar
  349. Status epilepticus: Practice variation and adherence to treatment guid...
    Go to citation Crossref Google Scholar
  350. Implementation Science to Improve Quality of Neurological Care
    Go to citation Crossref Google Scholar
  351. Association between benzodiazepine outpatient treatment and risk of ea...
    Go to citation Crossref Google Scholar
  352. Status epilepticus with prominent motor symptoms clusters into distinc...
    Go to citation Crossref Google Scholar
  353. Rapid administration of undiluted intravenous levetiracetam
    Go to citation Crossref Google Scholar
  354. Evidence-Based Protocols in Child Neurology
    Go to citation Crossref Google Scholar
  355. Hypoxic-Ischemic Encephalopathy-Induced Seizure in an 11-Year-Old Fema...
    Go to citation Crossref Google Scholar
  356. Repetitive Abnormalities
    Go to citation Crossref Google Scholar
  357. An Insight into the Current Understanding of Status Epilepticus: From ...
    Go to citation Crossref Google Scholar
  358. The Medial Septum as a Potential Target for Treating Brain Disorders A...
    Go to citation Crossref Google Scholar
  359. Efficacy and Safety of Ketamine in Refractory/Super-refractory Nonconv...
    Go to citation Crossref Google ScholarPub Med
  360. Seizures and epilepsy after intracerebral hemorrhage: an update
    Go to citation Crossref Google Scholar
  361. Comparison of the efficacy and safety of levetiracetam and phenytoin i...
    Go to citation Crossref Google Scholar
  362. A pharmacokinetic simulation study to assess the performance of a spar...
    Go to citation Crossref Google Scholar
  363. Convulsive Status Epilepticus in a Cohort of Patients from a Peruvian ...
    Go to citation Crossref Google Scholar
  364. Indications for Inpatient Magnetoencephalography in Children – An Inst...
    Go to citation Crossref Google Scholar
  365. A systematic review of second line therapies in toxic seizures
    Go to citation Crossref Google Scholar
  366. Epilepsy: recognition and management of seizures in children and young...
    Go to citation Crossref Google Scholar
  367. Lebensrettende Maßnahmen bei Kindern (Paediatric Life Support, PLS)
    Go to citation Crossref Google Scholar
  368. Assessment of benzodiazepine dosing strategies for the management of s...
    Go to citation Crossref Google Scholar
  369. Comparative profile of refractory status epilepticus models following ...
    Go to citation Crossref Google Scholar
  370. Evaluation of diazepam nasal spray in patients with epilepsy concomita...
    Go to citation Crossref Google Scholar
  371. Characteristics and outcome‐related factors of seizure at the first on...
    Go to citation Crossref Google Scholar
  372. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After...
    Go to citation Crossref Google Scholar
  373. 2020 Korean Guidelines for Cardiopulmonary Resuscitation. Part 5. Post...
    Go to citation Crossref Google Scholar
  374. Efficacy and Safety of Levetiracetam vs. Phenytoin as Second Line Anti...
    Go to citation Crossref Google Scholar
  375. A Comparison of Seizure Prophylaxis: Phenytoin Versus Levetiracetam
    Go to citation Crossref Google Scholar
  376. Early Neurologic Recovery, Practice Pattern Variation, and the Risk of...
    Go to citation Crossref Google Scholar
  377. Myeloid EP2 Receptors in Status Epilepticus—Peripheral But Not Negligi...
    Go to citation Crossref Google ScholarPub Med
  378. Pharmacotherapy for Nonconvulsive Seizures and Nonconvulsive Status Ep...
    Go to citation Crossref Google Scholar
  379. État de mal épileptique chez l’adulte : diagnostic et traitement
    Go to citation Crossref Google Scholar
  380. Not all patients with convulsive status epilepticus intubated in pre-h...
    Go to citation Crossref Google Scholar
  381. Neuroprotection by delayed triple therapy following sarin nerve agent ...
    Go to citation Crossref Google Scholar
  382. Levetiracetam for convulsive status epilepticus in childhood: systemat...
    Go to citation Crossref Google Scholar
  383. Simulation-Based Assessments and Graduating Neurology Residents' Miles...
    Go to citation Crossref Google Scholar
  384. Phenytoin Serum Concentrations in Patients With Left Ventricular Suppo...
    Go to citation Crossref Google ScholarPub Med
  385. European Resuscitation Council Guidelines 2021: Paediatric Life Suppor...
    Go to citation Crossref Google Scholar
  386. Preferred practices for rescue treatment of seizure clusters: A consen...
    Go to citation Crossref Google Scholar
  387. Time Is Brain: Acute Control of Repetitive Seizures and Status Epilept...
    Go to citation Crossref Google Scholar
  388. Absolute Bioavailability of Microdosed Midazolam After Buccal Administ...
    Go to citation Crossref Google Scholar
  389. Seizure action plans in the pediatric population with epilepsy: Uptake...
    Go to citation Crossref Google Scholar
  390. Benzodiazepines for Out-of-Hospital Status Epilepticus: Do or Do Not! ...
    Go to citation Crossref Google ScholarPub Med
  391. Treatment of acetylcholinesterase inhibitor-induced seizures with poly...
    Go to citation Crossref Google Scholar
  392. Revaccination outcomes of children with vaccine proximate seizures
    Go to citation Crossref Google Scholar
  393. Therapy delay in status epilepticus extends its duration and worsens i...
    Go to citation Crossref Google Scholar
  394. Patterns of benzodiazepine underdosing in the Established Status Epile...
    Go to citation Crossref Google Scholar
  395. Statewide Emergency Medical Services Protocols for Status Epilepticus ...
    Go to citation Crossref Google Scholar
  396. Consensus Statement on Analgo-sedation in Neurocritical Care and Revie...
    Go to citation Crossref Google Scholar
  397. Therapie des akuten epileptischen Anfalls beim Kind im Notfall
    Go to citation Crossref Google Scholar
  398. Emergency Neuropharmacology
    Go to citation Crossref Google Scholar
  399. Seizure Rescue Medications for Out-Of-Hospital Use in Children
    Go to citation Crossref Google Scholar
  400. Update on the management of status epilepticus
    Go to citation Crossref Google Scholar
  401. Emergency management of the paediatric patient with convulsive status ...
    Go to citation Crossref Google Scholar
  402. La prise en charge d’urgence du patient pédiatrique en état de mal épi...
    Go to citation Crossref Google Scholar
  403. Pearls and Pitfalls of Introducing Ketogenic Diet in Adult Status Epil...
    Go to citation Crossref Google Scholar
  404. Automated identification and quality measurement for pediatric convuls...
    Go to citation Crossref Google Scholar
  405. Electrocorticographic description of the effects of anticonvulsant dru...
    Go to citation Crossref Google Scholar
  406. Accuracy of Calculated Free Valproate Levels in Adult Patients With St...
    Go to citation Crossref Google Scholar
  407. Intramuscular Midazolam for treatment of Status Epilepticus
    Go to citation Crossref Google Scholar
  408. Neurological Disorders
    Go to citation Crossref Google Scholar
  409. Neurological Diseases in Pediatric Critical Care
    Go to citation Crossref Google Scholar
  410. Medication Induced Cardiotoxicity and Skin Reactions
    Go to citation Crossref Google Scholar
  411. Status Epilepticus Convulsive
    Go to citation Crossref Google Scholar
  412. Industrial Accident Induced Coma: A Multi-Disciplinary Perspective Wit...
    Go to citation Crossref Google Scholar
  413. Seizures and Status Epilepticus
    Go to citation Crossref Google Scholar
  414. Anticonvulsant Agents: Pharmacology and Biochemistry
    Go to citation Crossref Google Scholar
  415. Anticonvulsant Agents: Pharmacology and Biochemistry
    Go to citation Crossref Google Scholar
  416. Preferential Antiseizure Medications in Pediatric Patients with Convul...
    Go to citation Crossref Google Scholar
  417. Intranasal delivery of antiseizure drugs
    Go to citation Crossref Google Scholar
  418. References
    Go to citation Crossref Google Scholar
  419. Status Epilepticus
    Go to citation Crossref Google Scholar
  420. Neuropharmacology
    Go to citation Crossref Google Scholar
  421. The critical care literature 2019
    Go to citation Crossref Google Scholar
  422. The unmet need for rapid epileptic seizure termination (REST)
    Go to citation Crossref Google Scholar
  423. Convulsive status epilepticus in an emergency department in Cameroon
    Go to citation Crossref Google Scholar
  424. Intranasal fosphenytoin: The promise of phosphate esters in nose-to-br...
    Go to citation Crossref Google Scholar
  425. Super-Refractory Status Epilepticus: Prognosis and Recent Advances in ...
    Go to citation Crossref Google Scholar
  426. Valproic Acid as an Adjuvant Treatment for Generalized Convulsive Stat...
    Go to citation Crossref Google Scholar
  427. Antiepileptic Drug Therapy for Status Epilepticus
    Go to citation Crossref Google Scholar
  428. Treatments for Convulsive and Nonconvulsive Status Epilepticus in Adul...
    Go to citation Crossref Google Scholar
  429. Practice Changing Articles in Neuroanesthesiology and Neurocritical Ca...
    Go to citation Crossref Google Scholar
  430. Time is brain: Review of emergency management of status epilepticus in...
    Go to citation Crossref Google Scholar
  431. Effectiveness of Non-benzodiazepine Antiepileptic Drugs in Benzodiazep...
    Go to citation Crossref Google Scholar
  432. Supporting Precision Dosing in Drug Labeling
    Go to citation Crossref Google Scholar
  433. Different Attitudes in the Management of Different Types of Status Epi...
    Go to citation Crossref Google Scholar
  434. Detrimental effect of antiepileptic drugs dose in pediatric children w...
    Go to citation Crossref Google Scholar
  435. Probleme genug
    Go to citation Crossref Google Scholar
  436. Diagnosis and Treatment of Status Epilepticus
    Go to citation Crossref Google Scholar
  437. Status epilepticus as an initial manifestation of hepatic encephalopat...
    Go to citation Crossref Google Scholar
  438. Pharmacologic Management of Status Epilepticus
    Go to citation Crossref Google Scholar
  439. Prehospital midazolam use and outcomes among patients with out-of-hosp...
    Go to citation Crossref Google Scholar
  440. Sleep Architecture in Valproate-Induced Nocturnal Enuresis in Primary ...
    Go to citation Crossref Google ScholarPub Med
  441. Levetiracetam versus Phenytoin for the Pharmacotherapy of Benzodiazepi...
    Go to citation Crossref Google Scholar
  442. A retrospective, observational study of perampanel in refractory and s...
    Go to citation Crossref Google Scholar
  443. Principles of Pharmacotherapy of Seizures and Status Epilepticus
    Go to citation Crossref Google Scholar
  444. Acute Provoked Seizures—Work-Up and Management in Adults
    Go to citation Crossref Google Scholar
  445. Status Epilepticus—Work-Up and Management in Children
    Go to citation Crossref Google Scholar
  446. Status Epilepticus: Work-Up and Management in Adults
    Go to citation Crossref Google Scholar
  447. Treatment of established status epilepticus in the elderly - a study p...
    Go to citation Crossref Google Scholar
  448. Frequency and Implications of Complications in the ICU After Status Ep...
    Go to citation Crossref Google Scholar
  449. Development of a novel outcome prediction score (PEDSS) for pediatric ...
    Go to citation Crossref Google Scholar
  450. Lorazepam timing for acute convulsive seizure control (LoTASC)
    Go to citation Crossref Google Scholar
  451. Continuous EEG use and status epilepticus treatment in Australasia: a ...
    Go to citation Crossref Google Scholar
  452. First-line medication dosing in pediatric refractory status epilepticu...
    Go to citation Crossref Google Scholar
  453. Emergency seizure management
    Go to citation Crossref Google Scholar
  454. Aphasic status epilepticus in a tertiary referral center in Turkey: Cl...
    Go to citation Crossref Google Scholar
  455. Intravenous brivaracetam for the management of refractory focal non-co...
    Go to citation Crossref Google Scholar
  456. Epidemiology of status epilepticus in the United States: A systematic ...
    Go to citation Crossref Google Scholar
  457. Anesthetic Use In Status Epilepticus: A Concise Review
    Go to citation Crossref Google Scholar
  458. Ketamine to treat super-refractory status epilepticus
    Go to citation Crossref Google Scholar
  459. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Ass...
    Go to citation Crossref Google Scholar
  460. Clinical Feature and Outcome of Childhood Status Epilepticus in a Teac...
    Go to citation Crossref Google Scholar
  461. Assessment of midazolam pharmacokinetics in the treatment of status ep...
    Go to citation Crossref Google Scholar
  462. Use of a simulation-based mastery learning curriculum for neurology re...
    Go to citation Crossref Google Scholar
  463. Levetiracetam vs. phenytoin as 2nd-line treatment for status epileptic...
    Go to citation Crossref Google Scholar
  464. Efficacy and safety profile of intravenous levetiracetam versus phenyt...
    Go to citation Crossref Google Scholar
  465. The burden of decisional uncertainty in the treatment of status epilep...
    Go to citation Crossref Google Scholar
  466. Early risk stratification after resuscitation from cardiac arrest
    Go to citation Crossref Google Scholar
  467. Institutional Pediatric Convulsive Status Epilepticus Protocol Decreas...
    Go to citation Crossref Google Scholar
  468. Validation of the Status epilepticus severity score (STESS) at high-co...
    Go to citation Crossref Google Scholar
  469. Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive...
    Go to citation Crossref Google ScholarPub Med
  470. The Unease When Using Anesthetics for Treatment-Refractory Status Epil...
    Go to citation Crossref Google Scholar
  471. EEG Monitoring After Convulsive Status Epilepticus
    Go to citation Crossref Google Scholar
  472. A Theoretical Paradigm for Evaluating Risk–Benefit of Status Epileptic...
    Go to citation Crossref Google Scholar
  473. When and How to Treat Status Epilepticus: The Tortoise or the Hare?
    Go to citation Crossref Google Scholar
  474. Association of guideline publication and delays to treatment in pediat...
    Go to citation Crossref Google Scholar
  475. Therapeutic Options for Patients with Refractory Status Epilepticus in...
    Go to citation Crossref Google Scholar
  476. Intramuscular Versus Buccal Midazolam for Pediatric Seizures: A Random...
    Go to citation Crossref Google Scholar
  477. Clinical characteristics and prognosis in a large paediatric cohort wi...
    Go to citation Crossref Google Scholar
  478. Phenytoin versus fosphenytoin for second-line treatment of status epil...
    Go to citation Crossref Google Scholar
  479. Transcranial photobiomodulation attenuates pentylenetetrazole‐induced ...
    Go to citation Crossref Google Scholar
  480. Levetiracetam vs. Fosphenytoin for Second-Line Treatment of Status Epi...
    Go to citation Crossref Google Scholar
  481. Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in th...
    Go to citation Crossref Google Scholar
  482. Levetiracetam for Benzodiazepine-Refractory Status Epilepticus
    Go to citation Crossref Google Scholar
  483. Seizures during treatment of childhood acute lymphoblastic leukemia: A...
    Go to citation Crossref Google Scholar
  484. Evaluation of fosphenytoin, levetiracetam, and propofol as treatments ...
    Go to citation Crossref Google Scholar
  485. Choosing Anticonvulsant Medications to Manage Status Epilepticus
    Go to citation Crossref Google Scholar
  486. Reply to Dr. Capovilla on “Reply to the article “Management of status ...
    Go to citation Crossref Google Scholar
  487. Central nervous system emergencies in haematological malignancies
    Go to citation Crossref Google Scholar
  488. Predictors of outcome in refractory generalized convulsive status epil...
    Go to citation Crossref Google Scholar
  489. Phenobarbital as alternate anticonvulsant for organophosphate‐induced ...
    Go to citation Crossref Google Scholar
  490. Clinical outcomes and treatments effectiveness in status epilepticus r...
    Go to citation Crossref Google Scholar
  491. Efficacy, Safety, and Economics of Intravenous Levetiracetam for Statu...
    Go to citation Crossref Google Scholar
  492. Management of Urgent Medical Conditions at the End of Life
    Go to citation Crossref Google Scholar
  493. Levetiracetam versus phenytoin for the treatment of established status...
    Go to citation Crossref Google Scholar
  494. Treatment of generalized convulsive status epilepticus: An internation...
    Go to citation Crossref Google Scholar
  495. Second-line treatments in benzodiazepine-resistant convulsive status e...
    Go to citation Crossref Google Scholar
  496. Recommandations Formalisées d’Experts SRLF/SFMU : Prise en charge des ...
    Go to citation Crossref Google Scholar
  497. Towards Successes in the Management of Nonconvulsive Status Epilepticu...
    Go to citation Crossref Google Scholar
  498. Pre‐school Child with Seizures
    Go to citation Crossref Google Scholar
  499. Electrographic predictors of successful weaning from anaesthetics in r...
    Go to citation Crossref Google Scholar
  500. Efficacy of levetiracetam, fosphenytoin, and valproate for established...
    Go to citation Crossref Google Scholar
  501. Second-line anticonvulsants for paediatric convulsive status epileptic...
    Go to citation Crossref Google Scholar
  502. Sustainable Brain Activity and no End in Sight—What’s in It for Status...
    Go to citation Crossref Google ScholarPub Med
  503. Childhood Status Epilepticus: Current Status and Future Directions
    Go to citation Crossref Google Scholar
  504. Clinical Profile and Short-term Outcome of Pediatric Status Epilepticu...
    Go to citation Crossref Google Scholar
  505. Fosphenytoin in Status Epilepticus: The Ice Needs to be Broken
    Go to citation Crossref Google Scholar
  506. Pediatric Convulsive Status Epilepticus: Act Fast, No matter With What...
    Go to citation Crossref Google Scholar
  507. Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fo...
    Go to citation Crossref Google Scholar
  508. Refractory and Super-refractory Status Epilepticus
    Go to citation Crossref Google Scholar
  509. Electrical Status Epilepticus During Sleep: a Case Report of Postmorbi...
    Go to citation Crossref Google Scholar
  510. Buccal Midazolam Solution for the Management of Prolonged Acute Convul...
    Go to citation Crossref Google Scholar
  511. Efficacy and economic evaluation of delivery of care with tele-continu...
    Go to citation Crossref Google Scholar
  512. Effects of Antiepileptic Drug Tapering on Episodic Memory as Measured ...
    Go to citation Crossref Google Scholar
  513. Therapie des akuten epileptischen Anfalls
    Go to citation Crossref Google Scholar
  514. Safety and Tolerability of Rapid Administration Undiluted Levetiraceta...
    Go to citation Crossref Google Scholar
  515. Collaborative Management Strategies for Drug Shortages in Neurocritica...
    Go to citation Crossref Google Scholar
  516. Clinical Performance Measures for Neurocritical Care: A Statement for ...
    Go to citation Crossref Google Scholar
  517. From international guidelines to real-world practice consensus on inve...
    Go to citation Crossref Google Scholar
  518. A pragmatic approach to intravenous anaesthetics and electroencephalog...
    Go to citation Crossref Google Scholar
  519. Medical management of status epilepticus: Emergency room to intensive ...
    Go to citation Crossref Google Scholar
  520. Allosteric GABAA Receptor Modulators—A Review on the Most Recent Heter...
    Go to citation Crossref Google Scholar
  521. Sodium Valproate Improves Skin Flap Survival via Gamma-Aminobutyric Ac...
    Go to citation Crossref Google Scholar
  522. Case 4-2020: A 52-Year-Old Woman with Seizure Disorder and Wide-Comple...
    Go to citation Crossref Google Scholar
  523. Identification of Risk Factors for Refractory Status Epilepticus
    Go to citation Crossref Google ScholarPub Med
  524. Infrequent Monitoring of the Effects of Valproate and Carbamazepine Th...
    Go to citation Crossref Google ScholarPub Med
  525. Status epilepticus during correction of hyponatremia in a patient with...
    Go to citation Crossref Google ScholarPub Med
  526. Mechanisms of Psychiatric Comorbidities in Epilepsy
    Go to citation Crossref Google Scholar
  527. Status Epilepticus
    Go to citation Crossref Google Scholar
  528. Status Epilepticus
    Go to citation Crossref Google Scholar
  529. Emergent Treatment of Status Epilepticus
    Go to citation Crossref Google Scholar
  530. Continuous EEG Monitoring: Systems of Care
    Go to citation Crossref Google Scholar
  531. Therapeutic Hypothermia in Neurocritical Care
    Go to citation Crossref Google Scholar
  532. Pharmacological Challenges in Neurocritical Care
    Go to citation Crossref Google Scholar
  533. Pediatric Status Epilepticus
    Go to citation Crossref Google Scholar
  534. Anticonvulsant Agents: Phenytoin and Fosphenytoin
    Go to citation Crossref Google Scholar
  535. Guidelines on Anti-convulsant Agents
    Go to citation Crossref Google Scholar
  536. Anticonvulsive Drug Use in Status Therapy: Adults
    Go to citation Crossref Google Scholar
  537. Anticonvulsive Drug Use in Status Treatment in Children
    Go to citation Crossref Google Scholar
  538. Medication-Induced Neurotoxicity in Critically Ill Cancer Patients
    Go to citation Crossref Google Scholar
  539. Neuropharmacology
    Go to citation Crossref Google Scholar
  540. Pharmacotherapy for Pediatric Convulsive Status Epilepticus
    Go to citation Crossref Google Scholar
  541. Neurologische Intensivmedizin
    Go to citation Crossref Google Scholar
  542. Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphe...
    Go to citation Crossref Google Scholar
  543. Rational polytherapy in the treatment of cholinergic seizures
    Go to citation Crossref Google Scholar
  544. Therapeutic effect of intravenous levetiracetam in status epilepticus:...
    Go to citation Crossref Google Scholar
  545. PNESSE 1: Psychogenic status and status epilepticus: Could they be dis...
    Go to citation Crossref Google Scholar
  546. Pharmacological and non-pharmacological approaches to life threatening...
    Go to citation Crossref Google Scholar
  547. Health Care Professionals’ Views on Using Remote Measurement Technolog...
    Go to citation Crossref Google Scholar
  548. Status Epilepticus: The Slow and Agonizing Death of Phenytoin
    Go to citation Crossref Google Scholar
  549. Medication Use in Schools: Current Trends, Challenges, and Best Practi...
    Go to citation Crossref Google Scholar
  550. Comparison of diazepam and lorazepam for the emergency treatment of ad...
    Go to citation Crossref Google Scholar
  551. Treatment of Status Epilepticus
    Go to citation Crossref Google Scholar
  552. Clinical profile & management of children with seizures presenting to ...
    Go to citation Crossref Google Scholar
  553. Krampfanfälle
    Go to citation Crossref Google Scholar
  554. Ketogenic Diet for Refractory Status Epilepticus in Children
    Go to citation Crossref Google Scholar
  555. Lessons from the Established Status Epilepticus Treatment Trial
    Go to citation Crossref Google Scholar
  556. Early polytherapy for benzodiazepine-refractory status epilepticus
    Go to citation Crossref Google Scholar
  557. Intravenous antiepileptic drugs in adults with benzodiazepine-resistan...
    Go to citation Crossref Google Scholar
  558. Reporting specifications regarding epilepsy practice guidelines based ...
    Go to citation Crossref Google Scholar
  559. Update in Neurocritical Care: a summary of the 2018 Paris internationa...
    Go to citation Crossref Google Scholar
  560. Assessment of dose capping in phenytoin loading practices in the emerg...
    Go to citation Crossref Google Scholar
  561. Status epilepticus - time is brain and treatment considerations
    Go to citation Crossref Google Scholar
  562. Randomized Trial of Three Anticonvulsant Medications for Status Epilep...
    Go to citation Crossref Google Scholar
  563. Review of purchases of unapproved medications by the Veterans Health A...
    Go to citation Crossref Google Scholar
  564. Nonconvulsive Status Epilepticus in Patients with Altered Mental Statu...
    Go to citation Crossref Google Scholar
  565. Emergency management of status epilepticus in a high-fidelity simulati...
    Go to citation Crossref Google Scholar
  566. Levetiracetam und Phenytoin nach Versagen von Benzodiazepinen gleich w...
    Go to citation Crossref Google Scholar
  567. Convulsion Treated by a Physician-Staffed Helicopter
    Go to citation Crossref Google Scholar
  568. Effects of Diazepam and Ketamine on Pilocarpine-Induced Status Epilept...
    Go to citation Crossref Google Scholar
  569. Critical Care Management of Status Epilepticus at a Tertiary Care Univ...
    Go to citation Crossref Google Scholar
  570. Excitatory GABAergic signalling is associated with benzodiazepine resi...
    Go to citation Crossref Google Scholar
  571. Management of Epilepsy among Children in the Gaza Strip: A Multicenter...
    Go to citation Crossref Google Scholar
  572. Rates and Trends of Endotracheal Intubation in Patients With Status Ep...
    Go to citation Crossref Google Scholar
  573. A Trial of Real-Time Electrographic Seizure Detection by Neuro-ICU Nur...
    Go to citation Crossref Google Scholar
  574. Pediatric emergency department visit characteristics of the patients o...
    Go to citation Crossref Google Scholar
  575. Electroencephalographic seizures in critically ill children: Managemen...
    Go to citation Crossref Google Scholar
  576. Select topics in the management of critically ill children
    Go to citation Crossref Google Scholar
  577. Is it a Tie at This Point in the Game? Efficacy of Levetiracetam and P...
    Go to citation Crossref Google ScholarPub Med
  578. Im Kindesalter nach Versagen von Benzodiazepinen gleich wirksam
    Go to citation Crossref Google Scholar
  579. Neue Perspektiven für eine bessere Betreuung
    Go to citation Crossref Google Scholar
  580. Activation to Arrival
    Go to citation Crossref Google Scholar
  581. Seizure Rescue Medication Use among US Pediatric Epilepsy Providers: A...
    Go to citation Crossref Google Scholar
  582. Evaluation of first-line anticonvulsants to treat nerve agent-induced ...
    Go to citation Crossref Google Scholar
  583. Treatment of Seizures in Children and Adults in the Emergency Medical ...
    Go to citation Crossref Google Scholar
  584. Status Epilepticus Mortality—Improving or Status Quo?
    Go to citation Crossref Google Scholar
  585. A Systems Biology Approach for Personalized Medicine in Refractory Epi...
    Go to citation Crossref Google Scholar
  586. Prevention, Treatment, and Monitoring of Seizures in the Intensive Car...
    Go to citation Crossref Google Scholar
  587. Calorie Intake During Status Epilepticus and Outcome: A 5-Year Cohort ...
    Go to citation Crossref Google Scholar
  588. Underdosing of Benzodiazepines in Patients With Status Epilepticus Enr...
    Go to citation Crossref Google Scholar
  589. Seizure specificities in patients with antibody‐mediated autoimmune en...
    Go to citation Crossref Google Scholar
  590. Predicting the Functional Outcome of Adult Patients with Status Epilep...
    Go to citation Crossref Google Scholar
  591. Propofol-induced refractory status epilepticus at remission age in ben...
    Go to citation Crossref Google Scholar
  592. Successful Treatment of Super-Refractory Status Epilepticus with High-...
    Go to citation Crossref Google Scholar
  593. Application of Size and Maturation Functions to Population Pharmacokin...
    Go to citation Crossref Google Scholar
  594. FACTORS INFLUENCING CONTROL OF CONVULSIVE STATUS EPILEPTICUS IN CHILDR...
    Go to citation Crossref Google Scholar
  595. A Comparison of Parenteral Phenobarbital vs. Parenteral Phenytoin as S...
    Go to citation Crossref Google Scholar
  596. Meta-analysis and cost-effectiveness of second-line antiepileptic drug...
    Go to citation Crossref Google Scholar
  597. SODIUM VALPROATE VERSUS FOSPHENYTOIN FOR STATUS EPILEPTICUS IN CHILDRE...
    Go to citation Crossref Google Scholar
  598. Evaluation of Intravenous Phenytoin and Fosphenytoin Loading Doses: In...
    Go to citation Crossref Google ScholarPub Med
  599. Highlights From the Annual Meeting of the American Epilepsy Society 20...
    Go to citation Crossref Google ScholarPub Med
  600. Therapie des akuten konvulsiven Anfalls und Status epilepticus im Kind...
    Go to citation Crossref Google Scholar
  601. Levetiracetam versus phenytoin for second-line treatment of convulsive...
    Go to citation Crossref Google Scholar
  602. Levetiracetam no better than phenytoin in children with convulsive sta...
    Go to citation Crossref Google Scholar
  603. Communication Challenges: A Spotlight on New-Onset Refractory Status E...
    Go to citation Crossref Google Scholar
  604. Pediatric refractory and super-refractory status epilepticus
    Go to citation Crossref Google Scholar
  605. Timing in the treatment of status epilepticus: From basics to the clin...
    Go to citation Crossref Google Scholar
  606. Pathophysiology of convulsive status epilepticus
    Go to citation Crossref Google Scholar
  607. Conventional and quantitative EEG in status epilepticus
    Go to citation Crossref Google Scholar
  608. New onset refractory status epilepticus (NORSE)
    Go to citation Crossref Google Scholar
  609. Postvaccination Febrile Seizure Severity and Outcome
    Go to citation Crossref Google Scholar
  610. Duration of therapeutic coma and outcome of refractory status epilepti...
    Go to citation Crossref Google Scholar
  611. Bone fractures from generalized convulsive seizures and status epilept...
    Go to citation Crossref Google Scholar
  612. Untangling operational failures of the Status Epilepticus Severity Sco...
    Go to citation Crossref Google Scholar
  613. Treatment options in pediatric super-refractory status epilepticus
    Go to citation Crossref Google Scholar
  614. Guía para el manejo de las crisis epilépticas en cuidados paliativos: ...
    Go to citation Crossref Google Scholar
  615. Guidelines for seizure management in palliative care: proposal for an ...
    Go to citation Crossref Google Scholar
  616. Perampanel for treatment of status epilepticus in Austria, Finland, Ge...
    Go to citation Crossref Google Scholar
  617. Epilepsy Emergencies: Status Epilepticus, Acute Repetitive Seizures, a...
    Go to citation Crossref Google Scholar
  618. Sedatives in neurocritical care: an update on pharmacological agents a...
    Go to citation Crossref Google Scholar
  619. Roadmap for a competency‐based educational curriculum in epileptology:...
    Go to citation Crossref Google Scholar
  620. The Neuroprotective Effect of Astaxanthin on Pilocarpine-Induced Statu...
    Go to citation Crossref Google Scholar
  621. Emergency Medical Services Protocols for Generalized Convulsive Status...
    Go to citation Crossref Google Scholar
  622. A hospital-based study on caregiver preferences on acute seizure rescu...
    Go to citation Crossref Google Scholar
  623. Neurological Emergencies in the Intensive Care Unit
    Go to citation Crossref Google Scholar
  624. Intravenously Administered Ganaxolone Blocks Diazepam-Resistant Lithiu...
    Go to citation Crossref Google Scholar
  625. Factors predicting cessation of status epilepticus in clinical practic...
    Go to citation Crossref Google Scholar
  626. The Different Clinical Features Between Autoimmune and Infectious Stat...
    Go to citation Crossref Google Scholar
  627. Intravenous Corticosteroids as an Adjunctive Treatment for Refractory ...
    Go to citation Crossref Google Scholar
  628. Comparing the efficacy of sodium valproate and levetiracetam following...
    Go to citation Crossref Google Scholar
  629. Efficacy and Safety of Intravenous Levetiracetam Therapy for Repetitiv...
    Go to citation Crossref Google Scholar
  630. Refractory Status Epilepticus After the Middle Cerebral Artery Aneurys...
    Go to citation Crossref Google Scholar
  631. Dexamethasone as Abortive Treatment for Refractory Seizures or Status ...
    Go to citation Crossref Google ScholarPub Med
  632. Treatment of Seizures
    Go to citation Crossref Google Scholar
  633. Acute Medical Events: Falls, Seizures, CVAs, Urinary Retention, Cardia...
    Go to citation Crossref Google Scholar
  634. Medication-Induced Neurotoxicity in Critically Ill Cancer Patients
    Go to citation Crossref Google Scholar
  635. Seizures
    Go to citation Crossref Google Scholar
  636. Management of Intracranial Hypertension and Status Epilepticus
    Go to citation Crossref Google Scholar
  637. When It’s Not Just a Febrile Seizure: Epileptic Encephalopathy
    Go to citation Crossref Google Scholar
  638. Pharmacologic Management of Patients with Neurologic Disorders
    Go to citation Crossref Google Scholar
  639. Neurologic Complications after Kidney Transplantation
    Go to citation Crossref Google Scholar
  640. Simulating Status Epilepticus
    Go to citation Crossref Google Scholar
  641. Timing and selection of first antiseizure medication in patients with ...
    Go to citation Crossref Google Scholar
  642. Massive lamotrigine and bupropion overdose resulting in status epilept...
    Go to citation Crossref Google Scholar
  643. Progress in the Diagnosis and Treatment of Non-Convulsive Status Epile...
    Go to citation Crossref Google Scholar
  644. Desflurane administration for refractory status epilepticus: a case re...
    Go to citation Crossref Google Scholar
  645. Protocol-Driven Management of Convulsive Status Epilepticus at a Terti...
    Go to citation Crossref Google Scholar
  646. Stroke‐related epilepsy
    Go to citation Crossref Google Scholar
  647. Prolonged status epilepticus: Early recognition and prediction of full...
    Go to citation Crossref Google Scholar
  648. External validation of the epidemiology-based mortality score in statu...
    Go to citation Crossref Google Scholar
  649. Use of post-graduate students' research in evidence informed health po...
    Go to citation Crossref Google Scholar
  650. Status Epilepticus, Refractory Status Epilepticus, and Super-refractor...
    Go to citation Crossref Google Scholar
  651. Status epilepticus alert reduces time to administration of second-line...
    Go to citation Crossref Google Scholar
  652. Introducing NASN’s New Evidence-based Clinical Guideline: Students Wit...
    Go to citation Crossref Google ScholarPub Med
  653. Therapeutic coma for the treatment of status epilepticus
    Go to citation Crossref Google Scholar
  654. Fosphenytoin vs. continuous midazolam for pediatric febrile status epi...
    Go to citation Crossref Google Scholar
  655. What to Look for on Post-stroke Neuroimaging
    Go to citation Crossref Google Scholar
  656. Levetiracetam circulating concentrations and response in status epilep...
    Go to citation Crossref Google Scholar
  657. Altered Mental Status
    Go to citation Crossref Google Scholar
  658. Seizure Disorders
    Go to citation Crossref Google Scholar
  659. Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication...
    Go to citation Crossref Google Scholar
  660. Unusual cause of fever, vision loss and super refractory status epilep...
    Go to citation Crossref Google Scholar
  661. Multimodal Predictions of Super-Refractory Status Epilepticus and Outc...
    Go to citation Crossref Google Scholar
  662. Change in Management of Status Epilepticus With the Addition of Neuroi...
    Go to citation Crossref Google Scholar
  663. Emergency First-Line Anti-Seizure Medication for Seizures and Status E...
    Go to citation Crossref Google Scholar
  664. Levetiracetam
    Go to citation Crossref Google Scholar
  665. Seizures After Adult Cardiac Surgery and Interventional Cardiac Proced...
    Go to citation Crossref Google Scholar
  666. Parenteral phenobarbital in status epilepticus revisited: Mayo Clinic ...
    Go to citation Crossref Google Scholar
  667. Risk score predictive of mortality in status epilepticus according to ...
    Go to citation Crossref Google Scholar
  668. Rescue therapies for seizure emergencies: New modes of administration
    Go to citation Crossref Google Scholar
  669. Anesthetic drugs for the treatment of status epilepticus
    Go to citation Crossref Google Scholar
  670. Long-term outcomes of status epilepticus: A critical assessment
    Go to citation Crossref Google Scholar
  671. Seizures and epilepsy in the acute medical setting: presentation and m...
    Go to citation Crossref Google Scholar
  672. Dyke-Davidoff-Masson syndrome: an unusual case of late diagnosis
    Go to citation Crossref Google Scholar
  673. What is new: Talk about status epilepticus in the neonatal period
    Go to citation Crossref Google Scholar
  674. Hospital Emergency Treatment of Convulsive Status Epilepticus: Compari...
    Go to citation Crossref Google Scholar
  675. Systematic review of clobazam use in patients with status epilepticus
    Go to citation Crossref Google Scholar
  676. Benzodiazepine prescribing for children, adolescents, and young adults...
    Go to citation Crossref Google Scholar
  677. Is naloxone the best antidote to reverse tramadol-induced neuro-respir...
    Go to citation Crossref Google Scholar
  678. Practical Management of Epileptic Seizures and Status Epilepticus in A...
    Go to citation Crossref Google Scholar
  679. Electroencephalographic Patterns in Neurocritical Care: Pathologic Con...
    Go to citation Crossref Google Scholar
  680. Decreasing Seizure Treatment Time Through Quality Improvement Reduces ...
    Go to citation Crossref Google Scholar
  681. Convulsive status epilepticus management in adults and children: Repor...
    Go to citation Crossref Google Scholar
  682. Clinical utility of EMSE and STESS in predicting hospital mortality fo...
    Go to citation Crossref Google Scholar
  683. Fat, Pharmacokinetics, and Fosphenytoin: Bigger Doses May Be Better*
    Go to citation Crossref Google Scholar
  684. Determination of four antiepileptic drugs in plasma using ultra-perfor...
    Go to citation Crossref Google Scholar
  685. Inadequate benzodiazepine dosing may result in progression to refracto...
    Go to citation Crossref Google Scholar
  686. Intravenous Phenytoin in Convulsive Status Epilepticus: The Devil We (...
    Go to citation Crossref Google Scholar
  687. Influence of adjunctive lacosamide in patients with seizures: a system...
    Go to citation Crossref Google Scholar
  688. Optimizing parents' performance in anticonvulsant rescue medication ad...
    Go to citation Crossref Google Scholar
  689. Treatment outcomes after the introduction of a new seizure management ...
    Go to citation Crossref Google Scholar
  690. No. 360-Induced Abortion: Surgical Abortion and Second Trimester Medic...
    Go to citation Crossref Google Scholar
  691. No 360 - Avortement provoqué : avortement chirurgical et méthodes médi...
    Go to citation Crossref Google Scholar
  692. Ictal Interictal Continuum Patterns
    Go to citation Crossref Google Scholar
  693. Clinical utility of EEG in diagnosing and monitoring epilepsy in adult...
    Go to citation Crossref Google Scholar
  694. Nonconvulsive status epilepticus after convulsive status epilepticus: ...
    Go to citation Crossref Google Scholar
  695. Memantine decreases neuronal degeneration in young rats submitted to L...
    Go to citation Crossref Google Scholar
  696. Towards acute pediatric status epilepticus intervention teams: Do we n...
    Go to citation Crossref Google Scholar
  697. The relevance of timing in nonconvulsive status epilepticus: A series ...
    Go to citation Crossref Google Scholar
  698. Seizing the Opportunity: Exploring Barriers to Use of Transmucosal Mid...
    Go to citation Crossref Google Scholar
  699. Determination of minimal steady‐state plasma level of diazepam causing...
    Go to citation Crossref Google Scholar
  700. Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on...
    Go to citation Crossref Google Scholar
  701. The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target i...
    Go to citation Crossref Google Scholar
  702. Intranasale Medikamentengabe im Rettungsdienst
    Go to citation Crossref Google Scholar
  703. Newer Antiepileptic Drugs for Status Epilepticus in Adults: What’s the...
    Go to citation Crossref Google Scholar
  704. Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus...
    Go to citation Crossref Google Scholar
  705. Do Intravenous Benzodiazepines or Benzodiazepines by an Alternative Ro...
    Go to citation Crossref Google Scholar
  706. État de mal épileptiques : avancées récentes
    Go to citation Crossref Google Scholar
  707. Update on the management of status epilepticus
    Go to citation Crossref Google Scholar
  708. Healthcare Utilization Characteristics for Intranasal Midazolam Versus...
    Go to citation Crossref Google ScholarPub Med
  709. Cerebrospinal fluid findings in non-infectious status epilepticus
    Go to citation Crossref Google Scholar
  710. The effect of vagus nerve stimulator in controlling status epilepticus...
    Go to citation Crossref Google Scholar
  711. Quality improvement in neurology: Child neurology quality measure set
    Go to citation Crossref Google Scholar
  712. Seizures
    Go to citation Crossref Google Scholar
  713. Early Treatment of Convulsive Status Epilepticus
    Go to citation Crossref Google Scholar
  714. Pediatric Status Epilepticus: Initial Management and the Special Syndr...
    Go to citation Crossref Google Scholar
  715. Status Epilepticus in Critically Ill Children
    Go to citation Crossref Google Scholar
  716. Seizure Activity
    Go to citation Crossref Google Scholar
  717. Acute Seizures and Status Epilepticus
    Go to citation Crossref Google Scholar
  718. Intensive Care Management of Acute Encephalopathy and Encephalitis
    Go to citation Crossref Google Scholar
  719. Updates in Refractory Status Epilepticus
    Go to citation Crossref Google Scholar
  720. Sedation and analgesia in patients who need mechanical ventilation in ...
    Go to citation Crossref Google Scholar
  721. A nationwide multi-center questionnaire survey on the management and t...
    Go to citation Crossref Google Scholar
  722. Drug management for acute tonic-clonic convulsions including convulsiv...
    Go to citation Crossref Google Scholar
  723. Acute Systemic Complications of Convulsive Status Epilepticus—A System...
    Go to citation Crossref Google Scholar
  724. Sevoflurane for the treatment of refractory status epilepticus in the ...
    Go to citation Crossref Google Scholar
  725. Inhibition of monoacylglycerol lipase terminates diazepam‐resistant st...
    Go to citation Crossref Google Scholar
  726. A fatal case of valproate-induced hyperammonemic encephalopathy: An up...
    Go to citation Crossref Google Scholar
  727. Drug Treatment of Seizures and Epilepsy in Newborns and Children
    Go to citation Crossref Google Scholar
  728. Transition from intravenous to enteral ketamine for treatment of nonco...
    Go to citation Crossref Google Scholar
  729. Ist eine Akutbehandlung epileptischer Anfälle möglich und sinnvoll?
    Go to citation Crossref Google Scholar
  730. Impact of non-guideline-based treatment of status epilepticus
    Go to citation Crossref Google Scholar
  731. Management protocols for status epilepticus in the pediatric emergency...
    Go to citation Crossref Google Scholar
  732. Management protocols for status epilepticus in the pediatric emergency...
    Go to citation Crossref Google Scholar
  733. Evaluation of phenytoin serum levels following a loading dose in the a...
    Go to citation Crossref Google Scholar
  734. Rescue Medications in Epilepsy Patients: A Family Perspective
    Go to citation Crossref Google Scholar
  735. Providing teachers with education on epilepsy increased their willingn...
    Go to citation Crossref Google Scholar
  736. Nutritional and Bioenergetic Considerations in Critically Ill Patients...
    Go to citation Crossref Google Scholar
  737. Safety Threats During the Care of Infants with Hypoglycemic Seizures i...
    Go to citation Crossref Google Scholar
  738. États de mal épileptiques de l’adulte et de l’enfant
    Go to citation Crossref Google Scholar
  739. New onset status epilepticus in older patients: Clinical characteristi...
    Go to citation Crossref Google Scholar
  740. Adverse effects of phenytoin and fosphenytoin
    Go to citation Crossref Google Scholar
  741. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clin...
    Go to citation Crossref Google Scholar
  742. Spectrum and Predictors of Refractory Status Epilepticus in a Developi...
    Go to citation Crossref Google Scholar
  743. Intravenous lacosamide in status epilepticus: Correlation between load...
    Go to citation Crossref Google Scholar
  744. Population Pharmacokinetics and Exploratory Pharmacodynamics of Loraze...
    Go to citation Crossref Google Scholar
  745. When to Pick the Nose: Out-of-Hospital and Emergency Department Intran...
    Go to citation Crossref Google Scholar
  746. Top 100 cited articles on epilepsy and status epilepticus: A bibliomet...
    Go to citation Crossref Google Scholar
  747. Simultaneous triple therapy for the treatment of status epilepticus
    Go to citation Crossref Google Scholar
  748. Nonintravenous rescue medications for pediatric status epilepticus: A ...
    Go to citation Crossref Google Scholar
  749. Review article: Paediatric status epilepticus in the pre‐hospital sett...
    Go to citation Crossref Google Scholar
  750. Timing is everything: Where status epilepticus treatment fails
    Go to citation Crossref Google Scholar
  751. Missed diagnosis of prehospital status epilepticus
    Go to citation Crossref Google Scholar
  752. Standard operating procedures improve acute neurologic care in a sub-S...
    Go to citation Crossref Google Scholar
  753. Evaluation of a First Seizure and Management of Status Epilepticus
    Go to citation Crossref Google Scholar
  754. Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neu...
    Go to citation Crossref Google Scholar
  755. Acute and long‐term effects of brivaracetam and brivaracetam–diazepam ...
    Go to citation Crossref Google Scholar
  756. Intravenous Versus Nonintravenous Benzodiazepines for the Cessation of...
    Go to citation Crossref Google Scholar
  757. The efficacy of different kinds of intravenously applied antiepileptic...
    Go to citation Crossref Google Scholar
  758. Efficacy of levetiracetam versus fosphenytoin for the recurrence of se...
    Go to citation Crossref Google Scholar
  759. Status Epilepticus and Beyond: A Clinical Review of Status Epilepticus...
    Go to citation Crossref Google Scholar
  760. Seizures and epilepsy
    Go to citation Crossref Google Scholar
  761. Flat Out Unnecessary: Burst Characteristics, Not Duration of Interburs...
    Go to citation Crossref Google ScholarPub Med
  762. Status Epilepticus
    Go to citation Crossref Google Scholar
  763. Author response: Therapeutic coma for status epilepticus: Differing pr...
    Go to citation Crossref Google Scholar
  764. Newer Antiepileptic Drugs in Status Epilepticus: Prescription Trends a...
    Go to citation Crossref Google Scholar
  765. Challenges in the treatment of convulsive status epilepticus
    Go to citation Crossref Google Scholar
  766. Pharmacokinetics and pharmacodynamics of a new highly concentrated int...
    Go to citation Crossref Google Scholar
  767. Advancements in the critical care management of status epilepticus
    Go to citation Crossref Google Scholar
  768. Treatment of experimental status epilepticus with synergistic drug com...
    Go to citation Crossref Google Scholar
  769. Development and evaluation of midazolam in situ nasal gel properties i...
    Go to citation Crossref Google Scholar
  770. Glioblastoma in the limbic system presenting as sustained central hypo...
    Go to citation Crossref Google Scholar
  771. État de mal épileptiques
    Go to citation Crossref Google Scholar
  772. Critical Management of Status Epilepticus
    Go to citation Crossref Google Scholar
  773. Neurosteroid-sensitive δ-GABA A receptors:...
    Go to citation Crossref Google Scholar
  774. Algorithm for the treatment of status epilepticus: a New Zealand persp...
    Go to citation Crossref Google Scholar
  775. IV fosphenytoin in obese patients
    Go to citation Crossref Google Scholar
  776. Status Epilepticus - Lessons and Challenges from Animal Models
    Go to citation Crossref Google Scholar
  777. Case 9 Isoniazid Ingestion
    Go to citation Crossref Google Scholar
  778. Topiramate in the Treatment of Generalized Convulsive Status Epileptic...
    Go to citation Crossref Google Scholar
  779. Management of acute seizures in children: A review with special consid...
    Go to citation Crossref Google Scholar
  780. États de mal épileptiques de l’adulte et de l’enfant
    Go to citation Crossref Google Scholar
  781. Clinical presentation, epidemiology, neurophysiological findings, trea...
    Go to citation Crossref Google Scholar
  782. Treatment strategies of status epilepticus in the elderly: a report fr...
    Go to citation Crossref Google Scholar
  783. Continuous Infusion Antiepileptic Medications for Refractory Status Ep...
    Go to citation Crossref Google Scholar
  784. Epilepsy in pregnancy: Pharmacodynamics and pharmacokinetics
    Go to citation Crossref Google Scholar
  785. Levetiracetam treatment influences blood-brain barrier failure associa...
    Go to citation Crossref Google Scholar
  786. Seizure Treatment in Children Transported to Tertiary Care: Recommenda...
    Go to citation Crossref Google Scholar
  787. Status Epilepticus
    Go to citation Crossref Google Scholar
  788. Treating epileptic emergencies – pharmacological advances
    Go to citation Crossref Google Scholar
  789. Indicación de dosis de carga de fármacos antiepilépticos en un hospita...
    Go to citation Crossref Google Scholar
  790. Recent advances in epilepsy management
    Go to citation Crossref Google Scholar
  791. A review of intranasal formulations for the treatment of seizure emerg...
    Go to citation Crossref Google Scholar
  792. Midazolam–ketamine dual therapy stops cholinergic status epilepticus a...
    Go to citation Crossref Google Scholar
  793. Benzodiazepine‐refractory status epilepticus: pathophysiology and prin...
    Go to citation Crossref Google Scholar
  794. Treatment of Status Epilepticus
    Go to citation Crossref Google Scholar
  795. Vers de nouvelles recommandations françaises sur la prise en charge de...
    Go to citation Crossref Google Scholar
  796. Safety of antidepressants assessed, new convulsive status epilepticus ...
    Go to citation Crossref Google Scholar
  797. Fruitful Futility: What We Learned from a Failed Clinical Trial of Out...
    Go to citation Crossref Google ScholarPub Med
  798. Should We Treat Electroencephalographic Discharges in the Clinic or in...
    Go to citation Crossref Google Scholar
  799. Treatment of Established Status Epilepticus
    Go to citation Crossref Google Scholar
  800. Management of Status Epilepticus in Children
    Go to citation Crossref Google Scholar
  801. 19. Neurological Disorders
    Go to citation Crossref Google Scholar

Figures and tables

Figures & Media

Tables

View Options

View options

PDF/ePub

View PDF/ePub

Get access

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:

Alternatively, view purchase options below:

Access journal content via a DeepDyve subscription or find out more about this option.

Start 2 week free trial
Need help?

Also from Sage